## Original Investigation

# The State of US Health, 1990-2010 Burden of Diseases, Injuries, and Risk Factors 

US Burden of Disease Collaborators

IMPORTANCE Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy.

OBJECTIVES To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries.

DESIGN We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries. Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age. Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health. Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs. Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs. Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages.

RESULTS US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years. The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury. Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls. The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders. As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs. The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use. Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th.

CONCLUSIONS AND RELEVANCE From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable. However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations.

Editorial page 585 Author Video Interview at jama.com

Supplemental content at jama.com

The United States spends the most per capita on health care across all countries, ${ }^{1,2}$ lacks universal health coverage, and lags behind other high-income countries for life expectancy ${ }^{3}$ and many other health outcome measures. ${ }^{4}$ High costs with mediocre population health outcomes at the national level are compounded by marked disparities across communities, socioeconomic groups, and race and ethnicity groups. ${ }^{5,6}$ Although over-

DALYs disability-adjusted life-years
HALE healthy life expectancy
YLDs years lived with disability
YLLs years of life lost due to premature mortality all life expectancy has slowly risen, the increase has been slower than for many other high-income countries. ${ }^{3}$ In addition, in some US counties, life expectancy has decreased in the past 2 decades, particularly for women. ${ }^{7,8}$ Decades of health policy and legislative initiatives have been directed at these challenges; a recent example is the Patient Protection and Affordable Care Act, which is intended to address issues of access, efficiency, and quality of care and to bring greater emphasis to population health outcomes. ${ }^{9}$ There have also been calls for initiatives to address determinants of poor health outside the health sector including enhanced tobacco control initiatives, ${ }^{10-12}$ the food supply, ${ }^{13-15}$ physical environment, ${ }^{16,17}$ and socioeconomic inequalities. ${ }^{18}$

With increasing focus on population health outcomes that can be achieved through better public health, multisectoral action, and medical care, it is critical to determine which diseases, injuries, and risk factors are related to the greatest losses of health and how these risk factors and health outcomes are changing over time. The Global Burden of Disease (GBD) framework ${ }^{19}$ provides a coherent set of concepts, definitions, and methods to do this. The GBD uses multiple metrics to quantify the relationship of diseases, injuries, and risk factors with health outcomes, each providing different perspectives. Burden of disease studies using earlier variants of this approach have been published for the United States for $1996^{20-22}$ and for Los Angeles County, California. ${ }^{23}$ In addition, 12 major risk factors have also been compared for 2005. ${ }^{24}$

In this report, we use the GBD Study 2010 to identify the leading diseases, injuries, and risk factors associated with the burden of disease in the United States, to determine how these health burdens have changed over the last 2 decades, and to compare the United States with other Organisation for Economic Co-operation and Development (OECD) countries.

## Methods

The GBD 2010, a collaborative effort involving 488 scientists from 50 countries, quantified health loss from 291 diseases and injuries, 1160 clinical sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors for 187 countries from 1990 to 2010. The overall aim of the GBD 2010 was to synthesize the world's knowledge of descriptive epidemiology to facilitate comparisons across problems, over time, and across countries. Methods and summary results from the GBD 2010 for the world and 21 regions have been published. ${ }^{3,19,25-31} \mathrm{Sev}-$


#### Abstract

Box. Glossary of Terms Disability-adjusted life-years: a summary metric of population health. DALYs represent a health gap and, as such, measure the state of a population's health compared to a normative goal. The goal is for individuals to live the standard life expectancy in full health. DALYs are the sum of 2 components: years of life lost (YLLs) and years lived with disability (YLDs). Healthy life expectancy: the number of years that a person at a given age can expect to live in good health, taking into account mortality and disability. Years lived with disability: computed as the prevalence of different disease sequelae and injury sequelae multiplied by disability weights for that sequela. Disability weights are selected on the basis of surveys of the general population about the health loss associated with the health state related to the disease sequela. Years of life lost due to premature mortality: computed by multiplying the number of deaths at each age by a standard life expectancy at that age. The standard selected represents the normative goal for survival and has been computed based on the lowest recorded death rates across countries in 2010.


eral studies focusing on results for a specific disease or risk factor have also been published or are in preparation. ${ }^{32-34} \mathrm{Be}-$ cause the GBD 2010 uses a standardized approach for 187 countries, the results can be used to benchmark population health outcomes across different groups of nations. National burden of disease studies including a benchmarking component using the GBD 2010 have been completed for the United Kingdom ${ }^{32}$ and China. ${ }^{35}$ Details on the data, approaches to enhancing data quality and comparability, and statistical modeling and metrics for the GBD 2010 are published elsewhere. ${ }^{3,19,25-27,29-31}$

The GBD 2010 cause list has 291 diseases and injuries, which are organized in a hierarchy with up to 4 levels of disaggregation. We identified the key sequelae for each disease or injury. Sequelae could include the disease, such as diabetes, or the outcomes associated with that disease, such as diabetic foot, neuropathy, or retinopathy. Some clinical disorders were classified as a disease but could also be a consequence of another disease; for example, cirrhosis secondary to hepatitis $B$ is a consequence of hepatitis $B$ but was classified as a disease. Any outcome appears in the GBD cause and sequelae list only once to avoid double counting. The full list of risk factors, diseases, and sequelae and further details on their development since 1991 are published elsewhere. ${ }^{19}$ In total, the study included 1160 sequelae.

The GBD 2010 uses several metrics to report results on health loss related to specific diseases, injuries, and risk factors: deaths and death rates, years of life lost due to premature mortality (YLLs), prevalence and prevalence rates for sequelae, years lived with disability (YLDs), and disabilityadjusted life-years (DALYs) (Box). Years of life lost are computed by multiplying the number of deaths in each age group by a reference life expectancy at that age. The life expectancy at birth in the reference life table is 86.0 years based on the lowest observed death rates for each age group across countries in 2010 and is intended to be an achievable outcome. ${ }^{19}$

Years lived with disability are calculated from the prevalence of a sequela multiplied by the disability weight for that sequela, which reflects its severity on a continuum between no loss of health (which has a disability weight of 0 ) and complete loss of health (which has a weight of 1.0). The meaning of disability in the GBD differs from that in US legislation such as the Americans with Disabilities Act; in the GBD, disability refers to any short- or long-term health loss. DALYs are the sum of YLLs and YLDs. The GBD uses another indicator, healthy life expectancy (HALE), to summarize overall population health in a single number accounting for both length of life and levels of ill health experienced at different ages. ${ }^{27}$

Estimation of prevalence for each sequela began with a systematic analysis of published studies and data sources providing information on prevalence, incidence, remission, and excess mortality, such as the National Health and Nutrition Examination Surveys, ${ }^{36}$ State Inpatient Databases, ${ }^{37}$ the $\mathrm{Na}-$ tional Ambulatory Medical Care Survey, ${ }^{38,39}$ the National Hospital Ambulatory Medical Care Survey, ${ }^{40}$ the Medical Expenditure Panel Survey, ${ }^{41}$ the National Comorbidity Survey, ${ }^{42}$ the National Epidemiological Survey on Alcohol and Related Conditions, and disease surveillance reports from the Centers for Disease Control and Prevention. For most sequelae, estimates were made using a Bayesian metaregression tool developed for the GBD 2010 (DisMod-MR). The DisMod-MR program estimates a generalized negative binomial model with nested random effects for regions and countries and fixed effects (see Vos et al ${ }^{25}$ for details on the equations and estimation procedure). Source code for DisMod-MR is available at http://ihmeuw.org/dismod_mr. eTable 1 in the Supplement provides the estimated prevalences for the 1160 sequelae for the United States in 2010.

For the GBD 2010, disability weights were measured for 220 unique health states that cover the 1160 disease and injury sequelae. ${ }^{26}$ Disability weights were generated using data from more than 30000 respondents contacted through populationbased, random-sample surveys in the United States, Peru, Tanzania, Bangladesh, and Indonesia and through an open Internet survey. The US survey, conducted using computerassisted telephone interviews, consisted of 3323 respondents, and the Internet survey consisted of 7180 selfselecting respondents from the United States. Results from population surveys in developing countries and the United States were highly consistent, suggesting a common construct of health; likewise, the results from the well-educated respondents to the Internet survey were highly consistent with the population-based samples. For example, the correlation between results from the United States and from the combined sample was 0.97. ${ }^{26}$ The 220 disability weights used in this study and the lay descriptions used to elicit choices from survey respondents are published elsewhere. ${ }^{26}$ Uncertainty in the disability weight for each sequela was propagated into the estimates of YLDs for each disease and injury using standard simulation methods. ${ }^{43}$ Information on age-specific mortality rates and on overall age-specific YLDs per person was combined into an overall measure of HALE, using a standard approach to extending the life table to capture adjustments for nonfatal health outcomes. ${ }^{27}$

We estimated the deaths or DALYs related to the 67 risk factors or clusters of risk factors (eTables 7 and 8 in the Supplement) following the conceptual framework for risk factors developed for the GBD, which identifies 3 layers of factors in a causal web: distal socioeconomic, proximal behavioral and environmental, and physiological and pathophysiological causes. ${ }^{44}$ Computation follows 3 key steps.

In the first step, risk-outcome pairs were included when evidence met the criteria for "convincing" or "probable" evidence. ${ }^{45}$ As defined by the World Cancer Research Fund grading system, convincing evidence is evidence from epidemiological studies showing consistent associations between exposure and disease, with little or no evidence to the contrary. The evidence must come from a substantial number of studies including prospective observational studies and, when relevant, randomized controlled trials of sufficient size, duration, and quality showing consistent effects. The association should be biologically plausible, such as the effect of salt on fluid retention, increases in blood pressure, and ultimate effect on cardiovascular diseases. Probable evidence is defined as evidence based on epidemiological studies showing fairly consistent associations between exposure and disease but for which there are perceived shortcomings in the available evidence or some evidence to the contrary, which preclude a more definite judgment; for example, the effects of diets low in seafood omega-3 fatty acids on ischemic heart disease mortality. Shortcomings in the evidence may be any of the following: insufficient duration of trials (or studies), insufficient trials (or studies) available, inadequate sample sizes, or incomplete follow-up. Laboratory evidence is usually supportive and the association must again be biologically plausible. Relative risks of mortality and morbidity were estimated based on meta-analyses of the scientific literature. ${ }^{31}$ eTable 2 in the Supplement provides the published relative risks used for each of the risk factors used in the analysis.

In the second step, the distribution of each risk factor exposure in each country, age, and sex group was estimated from published and unpublished data sources. ${ }^{31}$

In the third step, deaths or DALYs associated with risk factors were estimated by comparing the current distribution of exposure with a theoretical minimum risk exposure distribution (TMRED) of exposure selected for each risk factor. The TMRED is a feasible distribution of exposure that would minimize population health risk. For example, the theoretical minimum risk distribution for tobacco is that no one has smoked in the past; for systolic blood pressure, it is a distribution with a mean of 110 to 115 mm Hg and a standard deviation of 6 mm Hg . The TMRED for each risk factor is the same for all populations; Lim et al ${ }^{31}$ provides detail on these distributions for dichotomous and continuous risk factors. TMREDs have been defined for each of the 14 subcomponents of diet. The overall relationship of diet with health outcomes assumes the contribution of each component is multiplicative; that is, that the individual dietary contributions are independent.

Each risk factor or cluster of risk factors was analyzed separately such that the sum of attributable fractions (see eTable 2 in the Supplement) for a disease or injury can be greater than
$100 \%$. For example, a behavioral risk factor, such as some components of diet, may operate in part through reducing blood pressure. We included only risks for which there was convincing or probable evidence for pairs of risk factors and specific outcomes and that had sufficient epidemiological data to estimate risk factor-specific effect sizes, eg, relative risks. These risks included a range of behavioral, environmental, and metabolic risk factors, but distal socioeconomic factors were excluded because much of the literature on these risk factors focuses on all-cause mortality and morbidity outcomes.

Using simulation methods, ${ }^{46,47}$ we took 1000 draws (unbiased random samples) from the uncertainty distribution of the relative risks, prevalence of exposure estimates, theoretical minimum risk distributions, and background outcome rates. Uncertainty intervals for burden related to a risk factor were based on computation of the results for each of the 1000 draws; the lower bound of the $95 \%$ uncertainty interval for the final quantity of interest is the 2.5 percentile of the distribution and the upper bound is the 97.5 percentile of the distribution. These uncertainty intervals reflect all sources of uncertainty, including sampling error and model parameter uncertainty, from each component of the analysis.

For outcomes measured for specific age groups (deaths, YLLs, YLDs, and DALYs), we directly computed agestandardized rates using the World Health Organization's age standard. ${ }^{48}$ For each disease, injury, or risk factor, we ranked countries in 1990 and 2010 by the age-standardized rates for each outcome measure. We compared US outcomes with those of the 34 countries that are members of the OECD. These OECD members have been used in other comparative studies for the United States. ${ }^{49}$ For a given country and disease, injury, or risk, we tested whether a country was significantly above the mean of all OECD countries, indistinguishable from the mean, or below the mean; we used a 1 -sided test at the $P<.05$ significance level.

## Results

## Years of Life Lost

Table 1 shows, for the 30 leading diseases and injuries contributing to premature mortality in the United States in 2010, the number of deaths and YLLs and their rates of change from 1990 to 2010. Table 1 also shows the change in the agestandardized death rate to distinguish changes relating to population growth and aging from changes in age-specific rates. Ischemic heart disease and stroke were the first and third leading diseases contributing to premature death in 2010, but both are declining in terms of the number of YLLs and agestandardized rates. Despite declines, $15.9 \%$ of YLLs were related to ischemic heart disease and $4.3 \%$ of YLLs were related to stroke, highlighting the continued dominance of cardiovascular diseases in premature death. Lung cancer and chronic obstructive pulmonary disease (COPD) were the second and fourth leading diseases contributing to YLLs, respectively. Both diseases are increasing in absolute terms but have declining age-standardized rates; declines in COPD are notably slower than those in lung cancer. Road injury (which includes bi-
cycle, motorcycle, motor vehicle, and pedestrian injury) and self-harm are the fifth and sixth leading diseases or injuries contributing to YLLs; in men, they are ranked third and fourth and in women, eighth and 16th, respectively.

The next 3 leading diseases contributing to YLLs, diabetes, cirrhosis and Alzheimer disease, all increased in rank and the number of YLLs from 1990 to 2010. Colorectal cancer (10th), breast cancer (13th for both sexes combined and fifth in women), and pancreatic cancer (18th) are in the top 20 diseases and injuries contributing to premature death. Other large increases in premature mortality were seen for drug use disorders (moving from 44th to 15th), chronic kidney disease (CKD) (from 21st to 16th), kidney cancer (from 35th to 24th), and poisonings (from 31st to 26th); falls (from 33rd to 29th) and liver cancer (from 39th to 30th) also increased. The increase in YLLs associated with liver cancer may be related to a hepatitis C cohort effect. ${ }^{50}$ Among the 30 leading diseases and injuries contributing to YLLs in 1990, declines of $25 \%$ or more were seen for interpersonal violence, preterm birth complications, congenital anomalies, HIV/AIDS, and sudden infant death syndrome. The YLLs related to HIV decreased by $64 \%$ and declined in rank from seventh to 23rd. eTables 3 and 4 in the Supplement provide estimates of deaths and YLLs, respectively, for all 223 diseases and injuries.

## Years Lived With Disability

Cardiovascular diseases, cancers, and chronic respiratory diseases are all related to YLDs, but the largest contributors are the mental and behavioral disorders and the musculoskeletal disorders (Figure 1). Table 2 provides details on the 30 leading diseases and injuries contributing to YLDs in 2010. The number of YLDs from the top 18 diseases and injuries increased between 1990 and 2010, driven mostly by the population increase and aging of the US population, as agestandardized rates have largely remain unchanged (Table 2). Of these 18 causes, age-standardized rates increased significantly ( $P<.05$ ) only for stroke. The top 8 conditions were the same in 1990 and 2010: low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, anxiety disorders, COPD, drug use disorders, and diabetes. Four more mental and behavioral disorders are in the top 20 YLDs: alcohol use disorders, schizophrenia, bipolar disorder, and dysthymia. Age-standardized rates increased by $20 \%$ or more from 1990 to 2010 for drug use disorders, stroke, and eating disorders (eTable 5 in the Supplement provides detailed estimates of YLDs for the 267 diseases and injuries).

## Disability-Adjusted Life-Years

Combining YLLs and YLDs into DALYs provides a summary metric of the leading contributors to health loss. In 1990, 40\% of DALYs were due to YLDs increasing to $45 \%$ in 2010. Figure 2 shows the rank of the leading diseases and injuries contributing to DALYs in 1990 and 2010. Communicable, maternal, neonatal, and nutritional disorders are red, noncommunicable causes are blue, and injuries are green. Diseases and injuries are connected by lines between 1990 and 2010. The top 15 diseases and risk factors contributing to DALYs are a complex mix of cardiovascular diseases (ischemic heart disease and stroke),

Table 1. Deaths and YLLs From the 30 Leading Diseases and Injuries Contributing to YLLs in the United States in 1990 and 2010 and Percentage Change From 1990 to 2010 in YLLs and Age-Standardized YLL Rates ${ }^{\text {a }}$

| Diseases and Injuries | YLL Rank |  | Deaths |  |  |  | YLLs |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | No. (in Thousands) |  | Median Change, \% |  | No. (in Thousands) |  | Median Change, \% |  |
|  | 1990 | 2010 | 1990 | 2010 | Deaths | $\begin{gathered} \text { Age- } \\ \text { Standardized } \\ \text { Death Rate } \end{gathered}$ | 1990 | 2010 | YLLs | AgeStandardized YLL Rate |
| Ischemic heart disease | $\begin{gathered} 1 \\ (1-1) \end{gathered}$ | $\begin{gathered} 1 \\ (1-1) \end{gathered}$ | $\begin{gathered} \hline 648.2 \\ (600.8-676.1) \end{gathered}$ | $\begin{gathered} 562.9 \\ (515.4-662.1) \end{gathered}$ | $\begin{aligned} & -14.4 \\ & (-20.6 \\ & \text { to 2.6) } \end{aligned}$ | $\begin{gathered} -43.6 \\ (-47.1 \text { to } \\ -33.2) \end{gathered}$ | $\begin{gathered} 8990.3 \\ (8386.2- \\ 9451.4) \end{gathered}$ | $\begin{gathered} 7164.5 \\ (6706.6- \\ 8198.2) \end{gathered}$ | $\begin{gathered} -21.2 \\ (-25.6 \text { to } \\ -9.1) \end{gathered}$ | $\begin{gathered} -45.2 \\ (-48.2 \text { to } \\ -38.1) \end{gathered}$ |
| Lung cancer | $\begin{gathered} 2 \\ (2-3) \end{gathered}$ | $\begin{gathered} 2 \\ (2-2) \end{gathered}$ | $\begin{gathered} 143.5 \\ (116.8-178.5) \end{gathered}$ | $\begin{gathered} 163.3 \\ (128.1-200.8) \end{gathered}$ | $\begin{gathered} 14.4 \\ (-1.1 \text { to } \\ 26.0) \end{gathered}$ | $\begin{aligned} & -22.5 \\ & (-31.8 \text { to } \\ & -14.7) \end{aligned}$ | $\begin{gathered} 2871.9 \\ (2325.8- \\ 3523.2) \end{gathered}$ | $\begin{gathered} 2987.7 \\ (2418.1- \\ 3731.2) \end{gathered}$ | $\begin{gathered} 3.6 \\ (-6.6 \text { to } \\ 17.4) \end{gathered}$ | $\begin{gathered} -30 \\ (-36.1 \text { to } \\ -18.9) \end{gathered}$ |
| Stroke | $\begin{gathered} 4 \\ (3-4) \end{gathered}$ | $\begin{gathered} 3 \\ (3-5) \end{gathered}$ | $\begin{gathered} 177.8 \\ (163.7-200.9) \end{gathered}$ | $\begin{gathered} 172.3 \\ (153.5-201.7) \end{gathered}$ | $\begin{gathered} -3 \\ (-13.6 \\ \text { to } 8.2) \end{gathered}$ | $\begin{gathered} -36.7 \\ (-43.0 \text { to } \\ -30.4) \end{gathered}$ | $\begin{gathered} 2250.4 \\ (2096.3- \\ 2543.6) \end{gathered}$ | $\begin{gathered} 1945.3 \\ (1741.8- \\ 2147.8) \end{gathered}$ | $\begin{gathered} -13.2 \\ (-21.5 \text { to } \\ -6.2) \end{gathered}$ | $\begin{gathered} -39.3 \\ (-45.6 \text { to } \\ -34.8) \end{gathered}$ |
| Chronic obstructive pulmonary disease | $\begin{gathered} 5 \\ (5-8) \end{gathered}$ | $\begin{gathered} 4 \\ (3-5) \end{gathered}$ | $\begin{gathered} 97.5 \\ (90.3-105.5) \end{gathered}$ | $\begin{gathered} 154.5 \\ (137.8-170.0) \end{gathered}$ | $\begin{aligned} & 58.3 \\ & (43.3 \text { to } \\ & 75.7) \end{aligned}$ | $\begin{gathered} 5.6 \\ (-3.0 \text { to } \\ 16.3) \end{gathered}$ | $\begin{gathered} 1416.1 \\ (1308.5- \\ 1534.0) \end{gathered}$ | $\begin{gathered} 1913.1 \\ (1720.9- \\ 2067.9) \end{gathered}$ | $\begin{gathered} 34.7 \\ (24.7 \text { to } \\ 47.1) \end{gathered}$ | $\begin{gathered} -5.8 \\ (-12.5 \text { to } \\ 2.7) \end{gathered}$ |
| Road injury | $\begin{gathered} 3 \\ (2-4) \end{gathered}$ | $\begin{gathered} 5 \\ (3-6) \end{gathered}$ | $\begin{gathered} 49.6 \\ (43.4-59.2) \end{gathered}$ | $\begin{gathered} 44.0 \\ (36.2-53.5) \end{gathered}$ | $\begin{array}{r} -11.7 \\ (-21.8 \\ \text { to } 3.4) \end{array}$ | $\begin{gathered} -30.2 \\ (-37.5 \text { to } \\ -17.7) \end{gathered}$ | $\begin{gathered} 2336.5 \\ (2022.5- \\ 2752.3) \end{gathered}$ | $\begin{gathered} 1873.2 \\ (1569.0- \\ 2280.1) \end{gathered}$ | $\begin{gathered} -20.4 \\ (-28.4 \text { to } \\ -4.3) \end{gathered}$ | $\begin{gathered} -33.3 \\ (-39.7 \text { to } \\ -19.4) \end{gathered}$ |
| Self-harm | $\begin{gathered} 6 \\ (5-10) \end{gathered}$ | $\begin{gathered} 6 \\ (5-10) \end{gathered}$ | $\begin{gathered} 33.7 \\ (25.6-43.7) \end{gathered}$ | $\begin{gathered} 37.3 \\ (27.6-47.1) \end{gathered}$ | $\begin{gathered} 10.8 \\ (-6.2 \text { to } \\ 26.7) \end{gathered}$ | $\begin{aligned} & -12.9 \\ & (-27.2 \text { to } \\ & -1.6) \end{aligned}$ | $\begin{gathered} 1393.8 \\ (1068.6- \\ 1808.7) \end{gathered}$ | $\begin{gathered} 1456.9 \\ (1066.1- \\ 1779.0) \end{gathered}$ | $\begin{gathered} 5.7 \\ (-13.2 \text { to } \\ 18.1) \end{gathered}$ | $\begin{gathered} -13.2 \\ (-28.3 \text { to } \\ --2.4) \end{gathered}$ |
| Diabetes | $\begin{gathered} 15 \\ (11-15) \end{gathered}$ | $\begin{gathered} 7 \\ (6-9) \end{gathered}$ | $\begin{gathered} 50.2 \\ (45.3-60.0) \end{gathered}$ | $\begin{gathered} 86.1 \\ (73.0-99.3) \end{gathered}$ | $\begin{gathered} 71.8 \\ (43.7 \text { to } \\ 97.1) \end{gathered}$ | $\begin{gathered} 17.3 \\ (-1.3 \text { to } \\ 32.4) \end{gathered}$ | $\begin{gathered} 875.0 \\ (788.0- \\ 1042.3) \end{gathered}$ | $\begin{gathered} 1392.4 \\ (1186.7- \\ 1568.1) \end{gathered}$ | $\begin{gathered} 60.1 \\ (34.5 \text { to } \\ 78.3) \end{gathered}$ | $\begin{gathered} 13.0 \\ (-5.4 \text { to } \\ 25.7) \end{gathered}$ |
| Cirrhosis | $\begin{gathered} 14 \\ (10-15) \end{gathered}$ | $\begin{gathered} 8 \\ (7-12) \end{gathered}$ | $\begin{gathered} 35.5 \\ (31.3-42.1) \end{gathered}$ | $\begin{gathered} 49.5 \\ (39.5-54.6) \end{gathered}$ | $\begin{gathered} 43.3 \\ (14.0 \text { to } \\ 56.0) \end{gathered}$ | $\begin{gathered} -2 \\ (-22.5 \text { to } \\ 6.4) \end{gathered}$ | $\begin{gathered} 917.3 \\ (808.7- \\ 1095.1) \end{gathered}$ | $\begin{aligned} & 1232.7 \\ & (966.2- \\ & 1364.7) \end{aligned}$ | $\begin{gathered} 37.9 \\ (9.8 \text { to } \\ 50.8) \end{gathered}$ | $\begin{gathered} -5.3 \\ (-23.8 \text { to } \\ 3.3) \end{gathered}$ |
| Alzheimer disease | $\begin{gathered} 32 \\ (23-38) \end{gathered}$ | $\begin{gathered} 9 \\ (6-20) \end{gathered}$ | $\begin{gathered} 27.0 \\ (19.8-45.7) \end{gathered}$ | $\begin{gathered} 158.3 \\ (75.8-237.4) \end{gathered}$ | $\begin{gathered} 524.3 \\ (136.8 \\ \text { to } \\ 877.4) \end{gathered}$ | $\begin{gathered} 289.6 \\ (56.5 \text { to } \\ 487.6) \end{gathered}$ | $\begin{gathered} 257.4 \\ (202.1- \\ 407.1) \end{gathered}$ | $\begin{aligned} & 1192.4 \\ & (637.0- \\ & 1648.1) \end{aligned}$ | $\begin{gathered} 391.6 \\ (128.5 \text { to } \\ 593.1) \end{gathered}$ | $\begin{gathered} 209.5 \\ (60.4 \text { to } \\ 315.7) \end{gathered}$ |
| Colorectal cancer | $\begin{gathered} 11 \\ (9-14) \end{gathered}$ | $\begin{gathered} 10 \\ (7-13) \end{gathered}$ | $\begin{gathered} 60.2 \\ (49.6-67.1) \end{gathered}$ | $\begin{gathered} 63.9 \\ (55.4-88.1) \end{gathered}$ | $\begin{gathered} 1.6 \\ (-9.4 \text { to } \\ 49.7) \end{gathered}$ | $\begin{gathered} -29.4 \\ (-36.1 \text { to } \\ 2.4) \end{gathered}$ | $\begin{aligned} & 1018.9 \\ & (855.4- \\ & 1127.3) \end{aligned}$ | $\begin{aligned} & 1073.6 \\ & (946.9- \\ & 1412.7) \end{aligned}$ | $\begin{gathered} 1.6 \\ (-7.6 \text { to } \\ 41.8) \end{gathered}$ | $\begin{gathered} -27.5 \\ (-33.9 \text { to } \\ -0.8) \end{gathered}$ |
| Lower respiratory tract infections | $\begin{gathered} 10 \\ (7-11) \end{gathered}$ | $\begin{gathered} 11 \\ (8-13) \end{gathered}$ | $\begin{gathered} 90.4 \\ (71.9-103.3) \end{gathered}$ | $\begin{gathered} 85.4 \\ (69.4-114.0) \end{gathered}$ | $\begin{gathered} -8.1 \\ (-27.8 \\ \text { to } 34.7) \end{gathered}$ | $\begin{gathered} -38.6 \\ (-49.7 \text { to } \\ -14.1) \end{gathered}$ | $\begin{aligned} & 1185.7 \\ & (996.4- \\ & 1303.8) \end{aligned}$ | $\begin{aligned} & 1031.8 \\ & (905.9- \\ & 1261.3) \end{aligned}$ | $\begin{gathered} -14.3 \\ (-26.1 \text { to } \\ 8.4) \end{gathered}$ | $\begin{gathered} -37.6 \\ (-44.9 \text { to } \\ -26.1) \end{gathered}$ |
| Interpersonal violence | $\begin{gathered} 8 \\ (5-13) \end{gathered}$ | $\begin{gathered} 12 \\ (7-16) \end{gathered}$ | $\begin{gathered} 25.2 \\ (17.7-30.9) \end{gathered}$ | $\begin{gathered} 19.9 \\ (15.9-28.3) \end{gathered}$ | $\begin{aligned} & -24.4 \\ & (-33.8 \\ & \text { to } 8.2) \end{aligned}$ | $\begin{gathered} -34.4 \\ (-42.7 \text { to } \\ -7.9) \end{gathered}$ | $\begin{aligned} & 1344.3 \\ & (948.9- \\ & 1660.1) \end{aligned}$ | $\begin{aligned} & 1019.1 \\ & (795.8- \\ & 1427.6) \end{aligned}$ | $\begin{gathered} -26.5 \\ (-36.0 \text { to } \\ 2.9) \end{gathered}$ | $\begin{gathered} -33.9 \\ (-42.8 \text { to } \\ -8.9) \end{gathered}$ |
| Breast cancer | $\begin{gathered} 12 \\ (11-14) \end{gathered}$ | $\begin{gathered} 13 \\ (12-16) \end{gathered}$ | $\begin{gathered} 43.2 \\ (40.4-47.0) \end{gathered}$ | $\begin{gathered} 42.6 \\ (37.4-47.5) \end{gathered}$ | $\begin{gathered} -1.2 \\ (-12.6 \\ \text { to } 10.0) \end{gathered}$ | $\begin{gathered} -33.4 \\ (-40.0 \text { to } \\ -26.6) \end{gathered}$ | $\begin{gathered} 953.7 \\ (890.0- \\ 1020.1) \end{gathered}$ | $\begin{gathered} 891.7 \\ (804.6- \\ 980.7) \end{gathered}$ | $\begin{gathered} -6.5 \\ (-14.3 \text { to } \\ 2.4) \end{gathered}$ | $\begin{aligned} & -35.9 \\ & (-41.0 \text { to } \\ & -29.8) \end{aligned}$ |
| Preterm birth complications | $\begin{gathered} 9 \\ (6-12) \end{gathered}$ | $\begin{gathered} 14 \\ (11-18) \end{gathered}$ | $\begin{gathered} 14.1 \\ (11.3-16.8) \end{gathered}$ | $\begin{gathered} 10.0 \\ (8.0-12.3) \end{gathered}$ | $\begin{gathered} -29.6 \\ (-45.9 \\ \text { to }-5.1) \end{gathered}$ | $\begin{gathered} -35.7 \\ (-50.5 \text { to } \\ -13.3) \end{gathered}$ | $\begin{aligned} & 1213.2 \\ & (970.1- \\ & 1440.7) \end{aligned}$ | $\begin{gathered} 858.4 \\ (687.4- \\ 1061.3) \end{gathered}$ | $\begin{gathered} -29.6 \\ (-45.9 \text { to } \\ -5.1) \end{gathered}$ | $\begin{gathered} -35.7 \\ (-50.5 \text { to } \\ -13.3) \end{gathered}$ |
| Drug use disorders | $\begin{gathered} 44 \\ (24-49) \end{gathered}$ | $\begin{gathered} 15 \\ (8-28) \end{gathered}$ | $\begin{gathered} 3.8 \\ (2.6-8.5) \end{gathered}$ | $\begin{gathered} 19.4 \\ (9.3-28.6) \end{gathered}$ | $\begin{gathered} 477.4 \\ (105.1 \\ \text { to } \\ 699.8) \end{gathered}$ | $\begin{gathered} 376.6 \\ (69.3 \text { to } \\ 559.6) \end{gathered}$ | $\begin{gathered} 174.1 \\ (118.4- \\ 399.1) \end{gathered}$ | $\begin{gathered} 840.6 \\ (387.6- \\ 1239.2) \end{gathered}$ | $\begin{gathered} 448.4 \\ (88.0 \text { to } \\ 673.8) \end{gathered}$ | $\begin{gathered} 376.6 \\ (65.3 \text { to } \\ 565.7) \end{gathered}$ |
| Chronic kidney disease | $\begin{gathered} 21 \\ (19-25) \end{gathered}$ | $\begin{gathered} 16 \\ 13-20) \end{gathered}$ | $\begin{gathered} 30.4 \\ (26.0-37.5) \end{gathered}$ | $\begin{gathered} 60.3 \\ (47.4-74.0) \end{gathered}$ | $\begin{gathered} 99 \\ (58.8 \text { to } \\ 141.4) \end{gathered}$ | $\begin{gathered} 33.9 \\ (7.8 \text { to } \\ 59.2) \end{gathered}$ | $\begin{gathered} 425.2 \\ (374.2- \\ 521.6) \end{gathered}$ | $\begin{gathered} 780.2 \\ (636.7- \\ 908.4) \end{gathered}$ | $\begin{gathered} 85.8 \\ (47.4 \text { to } \\ 112.2) \end{gathered}$ | $\begin{gathered} 32.4 \\ (4.2 \text { to } \\ 49.9) \end{gathered}$ |
| Other cardiovascular/ circulatory | $\begin{gathered} 16 \\ (16-18) \end{gathered}$ | $\begin{gathered} 17 \\ (15-19) \end{gathered}$ | $\begin{gathered} 40.9 \\ (38.6-43.3) \end{gathered}$ | $\begin{gathered} 56.6 \\ (50.5-63.7) \end{gathered}$ | $\begin{gathered} 38.2 \\ (21.8 \text { to } \\ 57.2) \end{gathered}$ | $\begin{gathered} -8.7 \\ (-17.8 \text { to } \\ 1.0) \end{gathered}$ | $\begin{gathered} 636.1 \\ (611.3- \\ 662.0) \end{gathered}$ | 765.4 (709.1824.0) | $\begin{gathered} 20.3 \\ (10.2 \text { to } \\ 30.2) \end{gathered}$ | $\begin{gathered} -14.4 \\ (-21.1 \text { to } \\ -7.6) \end{gathered}$ |
| Pancreatic cancer | $\begin{gathered} 19 \\ (16-23) \end{gathered}$ | $\begin{gathered} 18 \\ (13-23) \end{gathered}$ | $\begin{gathered} 28.6 \\ (21.7-39.1) \end{gathered}$ | $\begin{gathered} 39.0 \\ (28.7-52.8) \end{gathered}$ | $\begin{aligned} & 37 \\ & (15.5 \text { to } \\ & 58.7) \end{aligned}$ | $\begin{gathered} -4.9 \\ (-19.0 \text { to } \\ 8.4) \end{gathered}$ | $\begin{array}{r} 508.6 \\ (391.5- \\ 669.5) \end{array}$ | $\begin{gathered} 679.9 \\ (500.1- \\ 908.3) \end{gathered}$ | $\begin{gathered} 34.3 \\ (15.2 \text { to } \\ 51.4) \end{gathered}$ | $\begin{gathered} -6.3 \\ (-19.8 \text { to } \\ 5.6) \end{gathered}$ |
| Congenital anomalies | $\begin{gathered} 13 \\ (11-15) \end{gathered}$ | $\begin{gathered} 19 \\ (15-22) \end{gathered}$ | $\begin{gathered} 13.4 \\ (11.2-15.8) \end{gathered}$ | $\begin{gathered} 12.4 \\ (10.8-15.1) \end{gathered}$ | $\begin{gathered} -8.3 \\ (-18.1 \\ \text { to } 8.2) \end{gathered}$ | $\begin{gathered} -32.3 \\ (-39.0 \text { to } \\ -14.7) \end{gathered}$ | $\begin{gathered} 937.1 \\ (762.0- \\ 1086.5) \end{gathered}$ | $\begin{gathered} 660.8 \\ (579.6- \\ 842.1) \end{gathered}$ | $\begin{gathered} -31.3 \\ (-39.0 \text { to } \\ -6.8) \end{gathered}$ | $\begin{gathered} -41.1 \\ (-48.1 \text { to } \\ -18.3) \end{gathered}$ |
| Cardiomyopathy | $\begin{gathered} 18 \\ (16-19) \end{gathered}$ | $\begin{gathered} 20 \\ (13-22) \end{gathered}$ | $\begin{gathered} 30.7 \\ (26.2-32.7) \end{gathered}$ | $\begin{gathered} 36 \\ (30.9-46.7) \end{gathered}$ | $\begin{gathered} 15.4 \\ (-1.0 \text { to } \\ 71.3) \end{gathered}$ | $\begin{gathered} -22.9 \\ (-32.6 \text { to } \\ 18.0) \end{gathered}$ | $\begin{gathered} 622.7 \\ (533.7- \\ 659.8) \end{gathered}$ | $\begin{gathered} 659.4 \\ (571.7- \\ 908.0) \end{gathered}$ | $\begin{gathered} 3.3 \\ (-9.8 \text { to } \\ 63.1) \end{gathered}$ | $\begin{gathered} -24.2 \\ (-34.1 \text { to } \\ 18.2) \end{gathered}$ |
| Hypertensive heart disease | $\begin{gathered} 17 \\ (16-19) \end{gathered}$ | $\begin{gathered} 21 \\ (16-23) \end{gathered}$ | $\begin{gathered} 41.4 \\ (33.2-51.4) \end{gathered}$ | $\begin{gathered} 44.7 \\ (34.8-59.6) \end{gathered}$ | $\begin{gathered} 7.4 \\ (-10.5 \\ \text { to } 30.6) \end{gathered}$ | $\begin{gathered} -29.1 \\ (-39.2 \text { to } \\ -15.7) \end{gathered}$ | $\begin{gathered} 625.8 \\ (522.0- \\ 768.2) \end{gathered}$ | $\begin{gathered} 641.9 \\ (531.5- \\ 800.8) \end{gathered}$ | $\begin{gathered} 2.2 \\ (-10.3 \text { to } \\ 18.1) \end{gathered}$ | $\begin{gathered} -28.1 \\ (-37.2 \text { to } \\ -18.7) \end{gathered}$ |

Table 1. Deaths and YLLs From the 30 Leading Diseases and Injuries Contributing to YLLs in the United States in 1990 and 2010 and Percentage Change From 1990 to 2010 in YLLs and Age-Standardized YLL Rates ${ }^{\text {a }}$ (continued)

| Diseases and Injuries | YLL Rank | Deaths |  |  |  | YLLs |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | No. (in Thousands) |  | Median Change, \% |  | No. (in Thousands) |  | Median Change, \% |  |
|  | 19902010 | 1990 | 2010 | Deaths | Age- Standardized Death Rate | 1990 | 2010 | YLLs | AgeStandardized YLL Rate |
| Leukemia | $\begin{array}{cc} \hline 20 & 22 \\ (19-24) & (21-29) \end{array}$ | $\begin{gathered} 20.3 \\ (16.4-25.3) \end{gathered}$ | $\begin{gathered} 25.5 \\ (20.0-31.6) \end{gathered}$ | $\begin{aligned} & 25.9 \\ & (3.3 \text { to } \\ & 45.1) \end{aligned}$ | $\begin{gathered} -13 \\ (-25.2 \text { to } \\ -2.7) \end{gathered}$ | $\begin{gathered} \hline 458.3 \\ (373.9- \\ 562.8) \end{gathered}$ | $\begin{gathered} \hline 493.6 \\ (402.2- \\ 611.1) \end{gathered}$ | $\begin{gathered} 7.8 \\ (-3.7 \text { to } \\ 19.3) \end{gathered}$ | $\begin{gathered} -20.5 \\ (-28.9 \text { to } \\ -11.1) \end{gathered}$ |
| Human immunodeficiency virus/AIDS | $\begin{array}{cc} 7 & 23 \\ (5-9) & (22-27) \end{array}$ | $\begin{gathered} 28.6 \\ (25.6-31.9) \end{gathered}$ | $\begin{gathered} 12.1 \\ (10.6-13.7) \end{gathered}$ | $\begin{gathered} -57.7 \\ (-63.5 \\ \text { to } \\ -50.5) \end{gathered}$ | $\begin{gathered} -67.7 \\ (-72.1 \text { to } \\ -62.3) \end{gathered}$ | $\begin{gathered} 1351.1 \\ (1201.1- \\ 1508.5) \end{gathered}$ | $\begin{gathered} 479.2 \\ (417.4- \\ 542.2) \end{gathered}$ | $\begin{gathered} -64.5 \\ (-69.6 \text { to } \\ -58.1) \end{gathered}$ | $\begin{gathered} -71.6 \\ (-75.8 \text { to } \\ -66.5) \end{gathered}$ |
| Kidney cancers | $\begin{array}{cc} 35 & 24 \\ (28-45) & (16-31) \end{array}$ | $\begin{gathered} 10.7 \\ (7.5-14.2) \end{gathered}$ | $\begin{gathered} 24.4 \\ (17.1-39.8) \end{gathered}$ | $\begin{gathered} 114.9 \\ (60.0 \text { to } \\ 262.5) \end{gathered}$ | $\begin{gathered} 47 \\ (9.7 \text { to } \\ 146.3) \end{gathered}$ | $\begin{gathered} 216.9 \\ (152.7- \\ 282.0) \end{gathered}$ | $\begin{gathered} 475.7 \\ (334.5- \\ 796.4) \end{gathered}$ | $\begin{aligned} & 104.7 \\ & (53.1 \text { to } \\ & 247.1) \end{aligned}$ | $\begin{aligned} & 40.9 \\ & (5.7 \text { to } \\ & 144.0) \end{aligned}$ |
| Non-Hodgkin lymphoma | $\begin{array}{cc} 22 & 25 \\ (20-26) & (22-30) \end{array}$ | $\begin{gathered} 20 \\ (16.8-23.5) \end{gathered}$ | $\begin{gathered} 25.2 \\ (20.3-30.2) \end{gathered}$ | $\begin{gathered} 25.4 \\ (2.4 \text { to } \\ 52.4) \end{gathered}$ | $\begin{gathered} -14.6 \\ (-28.0 \text { to } \\ 3.5) \end{gathered}$ | $\begin{gathered} 407.8 \\ (339.9- \\ 465.4) \end{gathered}$ | $\begin{gathered} 451.6 \\ (375.7- \\ 541.7) \end{gathered}$ | $\begin{gathered} 8.6 \\ (-5.7 \text { to } \\ 38.5) \end{gathered}$ | $\begin{gathered} -23.6 \\ (-33.4 \text { to } \\ -0.2) \end{gathered}$ |
| Poisonings | $\begin{array}{cc} 31 & 26 \\ (22-38) & (18-45) \end{array}$ | $\begin{gathered} 5.9 \\ (4.5-9.6) \end{gathered}$ | $\begin{gathered} 11.4 \\ (4.2-16.2) \end{gathered}$ | $\begin{gathered} 117.1 \\ (-34.4 \\ \text { to } \\ 229.4) \end{gathered}$ | $\begin{gathered} 76.1 \\ (-46.7 \text { to } \\ 173.3) \end{gathered}$ | $\begin{array}{r} 263.6 \\ (201.7- \\ 433.8) \end{array}$ | $\begin{gathered} 485.7 \\ (172.9- \\ 693.0) \end{gathered}$ | $\begin{gathered} 108.1 \\ (-39.3 \text { to } \\ 220.0) \end{gathered}$ | $\begin{gathered} 74.3 \\ (-48.1 \text { to } \\ 173.5) \end{gathered}$ |
| Prostate cancer | $\begin{array}{cc} 23 & 27 \\ (18-35) & (16-35) \end{array}$ | $\begin{gathered} 30.8 \\ (16.6-44.3) \end{gathered}$ | $\begin{gathered} 35.9 \\ (20.8-65.4) \end{gathered}$ | $\begin{gathered} 9.7 \\ (-30.0 \\ \text { to } 89.7) \end{gathered}$ | $\begin{gathered} -25.2 \\ (-49.5 \text { to } \\ 26.6) \end{gathered}$ | $\begin{gathered} 417.9 \\ (223.7- \\ 599.7) \end{gathered}$ | $\begin{gathered} 445.6 \\ (250.9- \\ 787.1) \end{gathered}$ | $\begin{gathered} -1.6 \\ (-30.1 \text { to } \\ 62.4) \end{gathered}$ | $\begin{gathered} -29.6 \\ (-48.8 \text { to } \\ 15.5) \end{gathered}$ |
| Brain cancer | $\begin{array}{cc} 24 & 28 \\ (19-31) & (21-34) \end{array}$ | $\begin{gathered} 14 \\ (9.8-21.1) \end{gathered}$ | $\begin{gathered} 16.5 \\ (10.9-24.4) \end{gathered}$ | $\begin{gathered} 18 \\ (-8.1 \text { to } \\ 45.3) \end{gathered}$ | $\begin{gathered} -18 \\ (-33.4 \text { to } \\ -3.4) \end{gathered}$ | $\begin{gathered} 383.3 \\ (262.8- \\ 551.6) \end{gathered}$ | $\begin{gathered} 411.2 \\ (279.8- \\ 611.0) \end{gathered}$ | $\begin{gathered} 7.1 \\ (-9.9 \text { to } \\ 26.9) \end{gathered}$ | $\begin{gathered} -22 \\ (-33.8 \text { to } \\ -7.5) \end{gathered}$ |
| Falls | $\begin{array}{cc} 33 & 29 \\ (26-36) & (24-35) \end{array}$ | $\begin{gathered} 14.5 \\ (12.1-19.7) \end{gathered}$ | $\begin{gathered} 31.6 \\ (18.7-41.7) \end{gathered}$ | $\begin{gathered} 136.4 \\ (11.3 \text { to } \\ 220.9) \end{gathered}$ | $\begin{gathered} 52 \\ (-25.4 \text { to } \\ 96.0) \end{gathered}$ | $\begin{array}{r} 245.4 \\ (215.5- \\ 321.9) \end{array}$ | $\begin{gathered} 400.2 \\ (265.4- \\ 489.2) \end{gathered}$ | $\begin{gathered} 79.3 \\ (-3.6 \text { to } \\ 117.3) \end{gathered}$ | $\begin{gathered} 20.9 \\ (-30.3 \text { to } \\ 42.9) \end{gathered}$ |
| Liver cancer | $\begin{array}{cc} 39 & 30 \\ (33-43) & (25-35) \end{array}$ | $\begin{gathered} 9.3 \\ (8.3-11.9) \end{gathered}$ | $\begin{gathered} 19.5 \\ (13.3-22.7) \end{gathered}$ | $\begin{gathered} 118.4 \\ (36.1 \text { to } \\ 151.3) \end{gathered}$ | $\begin{gathered} 55.3 \\ (-4.9 \text { to } \\ 76.4) \end{gathered}$ | $\begin{gathered} 184.7 \\ (167.7- \\ 235.4) \end{gathered}$ | $\begin{gathered} 398.9 \\ (260.6- \\ 461.5) \end{gathered}$ | $\begin{gathered} 125.5 \\ (34.9 \text { to } \\ 156.5) \end{gathered}$ | $\begin{gathered} 58.5 \\ (-6.4 \text { to } \\ 80.5) \end{gathered}$ |

${ }^{\text {a }}$ Diseases and injuries contributing to years of life lost due to premature mortality (YLLs) are ranked by the magnitude of YLLs in 2010. 95\% uncertainty intervals are shown in parentheses for all data.
musculoskeletal disorders (low back pain, other musculoskeletal disorders, and neck pain), 1 cancer type (lung), mental and behavioral disorders (major depressive disorder, drug use disorder, and anxiety), COPD, diabetes, and 3 injury types (road injury, self-harm, and falls) (Figure 2). Of the 30 leading diseases and injuries contributing to DALYs, 10 (COPD, major depressive disorders, other musculoskeletal, diabetes, drug use disorders, Alzheimer, falls, cirrhosis, CKD, and osteoarthritis) increased by more than $30 \%$ from 1990 to 2010 (eTable 6 in the Supplement provides detail for the 272 diseases and injuries). Other disorders contributing to DALYs not in the top 30 that have also increased by more than $30 \%$ in the past 2 decades include liver cancer, atrial fibrillation, kidney cancers, eating disorders, and poisoning.

Figure 3 shows the number of deaths and the percentage of DALYs related to the 17 risk factors or risk factor clusters in 2010 each of which was associated with more than $0.1 \%$ of DALYs. The largest cluster of risk factors was the composition of diet, which was associated with $26 \%$ of deaths and $14 \%$ of DALYs (Figure 3). The overall composition of diet is made up of an analysis of 14 components of diet (eTables 7 and 8 in the Supplement provide further details for risks or clusters of risks for DALYs and associations with deaths, respectively). The most important dietary risks in the United States are diets low in fruits, low in nuts and seeds, high in sodium, high in processed meats, low in vegetables, and high in trans fats. Al-
though the DALYs related to tobacco, including secondhand smoke, declined by $9 \%$ from 1990 to 2010, tobacco remains the second leading risk factor after diet. In terms of DALYs, body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) greater than 21.0-23.0 is the third ranked risk factor, associated with $14 \%$ deaths and $11 \%$ of DALYs. High blood pressure (greater than $110-115 \mathrm{~mm} \mathrm{Hg}$ ), high fasting plasma glucose level (greater than $88-95 \mathrm{mg} / \mathrm{dL}$ [4.9$5.3 \mathrm{mmol} / \mathrm{L}]$ ), and physical inactivity or low activity are the next leading risk factors. DALYs related to high cholesterol levels (greater than $145-155 \mathrm{mg} / \mathrm{dL}$ [3.8-4.0 mmol/L]) declined by $36 \%$, decreasing from the fifth to the eighth leading risk factor. In contrast, the burden associated with drug use disorders increased by $64 \%$. Ambient particulate matter pollution remains in the top 10 risk factors associated with DALYs in the United States but declined by $35 \%$ since 1990.

## Comparison With OECD Countries

Health outcomes and health progress in the United States, compared with OECD countries, are shown in Table 3 and Table 4, which include multiple summary metrics: age-standardized death rates, age-standardized YLL rates, age-standardized YLD rates, life expectancy at birth, and HALE at birth. For all mor-tality-based metrics, the US rank declined between 1990 and 2010 to 27th or 28th among the 34 OECD countries. Citizens living in countries with a substantially lower gross domestic

Figure 1. Number of Years Lived With Disability by Age for 20 Broad Groups of Diseases and Injuries in the United States in 2010 for Both Sexes Combined

product and health expenditure per capita, such as Chile, Portugal, Slovenia, and South Korea, have lower mortality rates than those in the United States. In contrast, the United States ranks toward the top for YLDs, fifth in 1990 and sixth in 2010, but wide uncertainty intervals mean that some countries have rates that are statistically indistinguishable from the United States. Relatively high mortality and low disability rates nevertheless translated into a comparatively poor HALE rank of 26 in 2010 because of the comparatively smaller variation in YLD rates than in YLLs across the OECD countries.

The rank of the age-standardized YLL rates across OECD countries for the 25 leading diseases and risk factors related to premature mortality in the United States in 2010 is shown in Figure 4. Countries are ordered from the lowest agestandardized YLL rate to the highest at the bottom. For 15 of 25 causes, mortality in the United States is significantly above the OECD mean (Figure 4). The 3 diseases and injuries contributing to YLL with the greatest potential to reduce premature deaths compared with other OECD countries and with higher than mean rates are ischemic heart disease, lung cancer, and road injury. Other examples of higher than mean rates with substantial potential to reduce YLLs include interpersonal violence, COPD, preterm birth complications, and diabetes, followed by drug use disorders, Alzheimer disease, and poisonings.

The same comparative analysis for YLDs confirms that the United States performs much better on agestandardized YLDs than on age-standardized YLLs. The leading diseases and injuries with the potential to reduce YLDs are COPD, other musculoskeletal disorders, drug use disorders, and
sickle cell disorders. The higher prevalence of sickle cell disorders in the United States is also likely related to a higher birth prevalence than in other OECD countries. The eFigure in the Supplement shows the same benchmarking analysis for risk factors across the OECD countries. Although the mean value for high blood pressure related to DALYs in the United States is lower than the mean of all OECD countries, blood pressure is seventh on the list of potential targets for reducing disease burden in the population. The biggest potential for burden reduction is high BMI, followed by tobacco use, dietary risks, alcohol use, and high fasting glucose levels. For each of these risk factors, the United States has a greater associated burden than the OECD mean.

## Discussion

Overall, population health in the United States improved from 1990 to 2010. Life expectancy at birth and HALE increased and all-cause death rates at all ages decreased. Although life span has increased, age-specific YLD rates have remained relatively stable, so the sharply increasing age gradient of YLD means that the overall volume of YLDs has increased in an aging US population, with an increase in the number of years lived with disability for the average American. The gap between life expectancy and HALE, a measure of the expected number of healthy years that an individual loses to disability-increased from 9.4 years to 10.1 years. In other words, individuals in the United States are living longer but are not necessarily in good health.

Table 2. YLD Numbers in 1990 and 2010 for Both Sexes Combined for the 30 Leading Diseases and Injuries Contributing to YLDs in 2010 in the United States and Percentage Change From 1990 to 2010, Ranked by the Magnitude of YLDs in 2010a

| Diseases and Injuries | YLD Rank |  | No. of YLDs (in Thousands) |  | Median Change, \% |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1990 | 2010 | 1990 | 2010 | YLDs | Age-Standardized YLD Rate |
| Low back pain | 1 (1-3) | 1 (1-3) | 2538.00 (1771.4-3427.2) | 3180.60 (2179.5-4318.6) | 24.9 (13.8 to 38.4) | -3 (-11.6 to 7.3) |
| Major depressive disorder | 2 (1-5) | 2 (1-4) | 2142.50 (1525.2-2843.7) | 3048.90 (2151.3-4122.3) | 42.7 (9.2 to 83.3) | 13.4 (-12.9 to 46.3) |
| Other musculoskeletal disorders | 3 (1-4) | 3 (2-4) | 2024.40 (1664.7-2311.9) | 2602.50 (2138.0-2986.8) | 28.5 (18.9 to 38.9) | -0.2 (-8.0 to 7.8) |
| Neck pain | 4 (2-6) | 4 (2-6) | 1652.70 (1151.0-2296.4) | 2134.40 (1482.6-2934.4) | 29.1 (17.4 to 41.1) | 0.2 (-9.1 to 9.5) |
| Anxiety disorders | 5 (2-6) | 5 (3-6) | 1541.00 (1078.5-2172.8) | 1866.10 (1310.2-2569.3) | 21.3 (4.7 to 39.5) | -1.5 (-15.2 to 13.1) |
| Chronic obstructive pulmonary disease | 6 (4-9) | 6 (3-10) | 1304.10 (761.3-2007.2) | 1745.40 (1011.9-2601.4) | 34.1 (4.6 to 70.9) | -1.5 (-23.2 to 25.0) |
| Drug use disorders | 7 (6-10) | 7 (6-10) | 996.9 (722.3-1337.9) | 1295.50 (921.6-1725.1) | 29.8 (6.5 to 58.6) | 20.1 (-1.4 to 47.1) |
| Diabetes | 8 (7-15) | 8 (6-11) | 747.7 (506.1-1059.3) | 1164.90 (789.1-1648.6) | 56.2 (38.4 to 74.8) | 11.2 (-1.4 to 24.5) |
| Osteoarthritis | 12 (8-19) | 9 (7-17) | 637.6 (393.1-972.0) | 994 (611.5-1471.0) | 56.1 (28.3 to 88.3) | 5.5 (-13.7 to 27.8) |
| Asthma | 9 (7-19) | 10 (7-19) | 769.3 (418.1-1229.5) | 932 (504.7-1469.3) | 21.2 (11.5 to 31.6) | -0.8 (-9.4 to 8.2) |
| Falls | 15 (10-20) | 11 (9-18) | 561.9 (381.4-801.1) | 864.3 (588.6-1224.8) | 54.1 (33.1 to 80.0) | 9.6 (-6.4 to 29.4) |
| Alzheimer disease | 17 (12-21) | 12 (10-17) | 532.2 (375.9-714.7) | 829.9 (594.9-1090.8) | 56 (43.9 to 68.9) | 3.8 (-4.1 to 11.8) |
| Alcohol use disorders | 10 (8-17) | 13 (8-19) | 688.1 (437.3-1018.7) | 835.7 (535.8-1222.1) | 21.4 (-10.3 to 63.6) | -1.6 (-27.3 to 32.6) |
| Migraine | 11 (8-18) | 14 (8-19) | 676.8 (444.7-938.5) | 805 (525.4-1136.3) | 18.9 ( 5.5 to 34.4) | -2.6 (-13.8 to 10.0) |
| Schizophrenia | 13 (8-19) | 15 (8-20) | 644.2 (410.3-884.9) | 825.3 (527.8-1150.1) | 27.9 (16.5 to 40.4) | -1.8 (-11.1 to 8.0) |
| Ischemic heart disease | 16 (10-21) | 16 (10-21) | 547.1 (351.0-797.0) | 685 (452.2-975.1) | 25.4 (12.9 to 40.6) | -14.3 (-22.6 to -4.3) |
| Stroke | 23 (20-28) | 17 (14-20) | 320.5 (263.3-375.9) | 628.7 (520.2-729.0) | 96.4 (82.6 to 110.9) | 40 (30.4 to 49.6) |
| Bipolar disorder | 18 (10-25) | 18 (11-26) | 481 (304.6-709.5) | 578 (358.3-854.8) | 20.3 (2.2 to 40.7) | 1.4 (-14.0 to 18.8) |
| Other hearing loss | 14 (7-22) | 19 (11-26) | 585.3 (336.5-967.1) | 559.2 (322.5-916.4) | -4.3 (-17.2 to 10.1) | -34.1 (-43.4 to -23.8) |
| Dysthymia | 19 (12-27) | 20 (14-27) | 435.9 (286.5-606.0) | 545.5 (355.1-765.3) | 25 (12.3 to 40.3) | -1.2 (-11.4 to 10.7) |
| Sickle cell disorder | 21 (11-30) | 21 (14-30) | 372.6 (202.6-729.4) | 472 (272.3-882.5) | 28.4 (-21.5 to 109.4) | 10.2 (-33.9 to 86.1) |
| Chronic kidney disease | 27 (21-30) | 22 (19-29) | 285.2 (203.9-372.1) | 410.4 (294.3-545.6) | 43.8 (28.5 to 61.3) | 4.4 (-6.7 to 17.9) |
| Rheumatoid arthritis | 24 (20-30) | 23 (20-29) | 313.9 (223.9-409.4) | 403.1 (288.2-528.3) | 28.3 (18.0 to 39.3) | -4.8 (-12.7 to 3.2) |
| Benign prostatic hyperplasia | 28 (21-34) | 24 (19-30) | 258.4 (167.4-389.5) | 396.8 (247.6-604.7) | 54 (17.0 to 96.3) | 3.2 (-22.1 to 32.4) |
| Eczema | 25 (18-35) | 25 (18-34) | 303.8 (156.7-483.5) | 390.2 (202.4-619.6) | 28.7 (16.3 to 41.2) | 7.1 (-4.0 to 18.0) |
| Road injury | 22 (18-29) | 26 (20-31) | 325.9 (214.0-470.3) | 373.1 (249.0-545.9) | 14.5 (-7.3 to 41.9) | -9.9 (-26.8 to 12.1) |
| Other vision loss | 29 (16-41) | 27 (14-39) | 270.6 (118.8-551.2) | 375 (162.2-762.4) | 39.3 (-20.6 to 151.1) | 0.7 (-42.6 to 81.0) |
| Edentulism | 20 (14-28) | 28 (22-37) | 386.2 (220.2-618.2) | 314.5 (182.1-499.4) | -18.9 (-28.5 to -7.3) | -41.9 (-48.9 to -33.7) |
| Diarrheal diseases | 26 (20-30) | 29 (25-36) | 293.8 (196.1-418.1) | 283.3 (189.8-409.5) | -3.4 (-14.9 to 7.2) | -21.9 (-31.1 to -12.9) |
| Epilepsy | 30 (26-37) | 30 (25-37) | 208.6 (157.3-268.1) | 260.7 (199.7-334.6) | 25 (10.5 to 41.7) | 2.9 (-9.0 to 17.0) |

Abbreviation: YLD, years lived with disability.
a $95 \%$ uncertainty intervals are shown in parentheses for all data.

Morbidity and chronic disability now account for nearly half of the health burden in the United States. The key contributors to this burden, however, are not the same as the major diseases and injuries contributing to premature mortality. Mental and behavioral disorders, musculoskeletal disorders, vision and hearing loss, anemias, and neurological disorders all contribute to the increases in chronic disability. Research and development has been much more successful at finding solutions for cardiovascular diseases and some cancers and their associated risk factors than for these leading causes of disability. These conditions receive less National Institutes of Health funding than cardiovascular diseases and cancers. ${ }^{51}$ The progressive and likely irreversible shift in the disease burden profile to these causes also has implications for the type of resources needed in the US health system.

Diet, BMI, and Disease Burden
In this analysis, the aggregate of the 14 subcomponents of diet is a more important factor associated with disease burden than either physical inactivity or high BMI. The effect sizes for dietary components were based on meta-analyses of observational cohort studies and for selected dietary components, on intervention studies. ${ }^{31,52,53}$ The results for diet are limited by difficulties in measurement, various levels of conflicting evidence, and potential influence of unmeasured confounders and mediators. In addition, because each component of diet is analyzed separately, the complex relationships among components of diet may not be fully considered or understood, which might overestimate the effects of each component. For example, individuals who consume large amounts of fruit also

Figure 2. Disability-Adjusted Life-Year Ranks for the Top 30 Diseases and Injuries in 1990 and 2010 and Percentage Change Between 1990 and 2010

|  | 1990 | 2010 |  | Median change, \% (95\% UI) |
| :---: | :---: | :---: | :---: | :---: |
| Mean rank (95\% UI) | Disease or injury | Disease or injury | Mean rank (95\% UI) |  |
| 1.0 (1-1) | 1 Ischemic heart disease | 1 Ischemic heart disease | 1.0 (1-1) | -19 (-23 to-7) |
| 2.8 (2-6) | 2 Lung cancer | 2 Chronic obstructive pulmonary disease | 2.5 (2-4) | 34 (19 to 52) |
| 3.9 (2-7) | 3 Chronic obstructive pulmonary disease | 3 Low back pain | 4.4 (2-10) | 25 (14 to 38) |
| 4.2 (2-7) | 4 Road injury | 4 Lung cancer | 4.4 (2-8) | 4 (-6 to 18) |
| 4.9 (2-7) | 5 Stroke | 5 Major depressive disorder | 4.9 (2-10) | 43 (9 to 83) |
| 5.1 (2-8) | 6 Low back pain | 6 Other musculoskeletal | 5.5 (3-8) | 34 (24 to 45) |
| 7.2 (3-11) | 7 Major depressive disorder | 7 Stroke | 7.3 (5-10) | 0 (-8 to 7) |
| 7.5 (6-9) | 8 Other musculoskeletal | 8 Diabetes | 7.4 (4-10) | 58 (43 to 71) |
| 10.3 (8-14) | 9 Diabetes | 9 Road injury | 9.8 (7-13) | -16 (-24 to -1) |
| 10.8 (7-17) | 10 Neck pain | 10 Drug use disorders | 10.4 (6-13) | 85 (37 to 129) |
| 11.4 (9-14) | 11 HIV/AIDS | 11 Neck pain | 10.5 (6-14) | 29 (17 to 41) |
| 11.9 (7-18) | 12 Anxiety disorders | 12 Alzheimer disease | 11.3 (8-14) | 159 (84 to 229) |
| 13.6 (9-21) | 13 Interpersonal violence | 13 Anxiety disorders | 12.1 (8-15) | 21 (5 to 40) |
| 13.6 (9-19) | 14 Self-harm | 14 Self-harm | 14.6 (12-21) | 6 (-13 to 18) |
| 14.0 (10-18) | 15 Preterm birth complications | 15 Falls | 17.0 (14-24) | 58 (29 to 84) |
| 15.9 (13-19) | 16 Lower respiratory tract infections | 16 Cirrhosis | 17.0 (14-25) | 38 (10 to 50) |
| 17.2 (11-22) | 17 Drug use disorders | 17 Chronic kidney disease | 18.0 (15-23) | 69 (45 to 86) |
| 18.5 (16-22) | 18 Colorectal cancer | 18 Colorectal cancer | 19.3 (14-24) | 3 (-6 to 42) |
| 18.8 (17-21) | 19 Breast cancer | 19 Alcohol use disorders | 20.0 (14-27) | 26 (-1 to 59) |
| 20.0 (16-24) | 20 Congenital anomalies | 20 Lower respiratory tract infections | 20.7 (15-25) | -13 (-24 to 9) |
| 21.8 (18-25) | 21 Cirrhosis | 21 Breast cancer | 21.9 (18-26) | -2 (-9 to 7) |
| 22.4 (16-29) | 22 Alcohol use disorders | 22 Interpersonal violence | 22.0 (14-28) | -26 (-35 to 3) |
| 22.9 (15-33) | 23 Asthma | 23 Preterm birth complications | 22.7 (16-27) | -25 (-40 to -2) |
| 24.8 (20-30) | 24 Falls | 24 Asthma | 22.7 (14-34) | 14 (6 to 24) |
| 25.4 (21-31) | 25 Alzheimer disease | 25 Osteoarthritis | 23.9 (15-34) | 56 (28 to 88) |
| 25.7 (23-29) | 26 Other cardiovascular and circulatory | 26 Other cardiovascular and circulatory | 24.2 (19-28) | 27 (16 to 40) |
| 28.0 (24-31) | 27 Chronic kidney disease | 27 Schizophrenia | 28.4 (19-37) | 29 (17 to 42) |
| 29.2 (22-38) | 28 Migraine | 28 Migraine | 28.5 (20-37) | 19 (5 to 34) |
| 30.1 (26-33) | 29 Cardiomyopathy | 29 Congenital anomalies | 28.9 (25-33) | -26 (-34 to -3) |
| 30.5 (25-35) | 30 Hypertensive heart disease | 30 Cardiomyopathy | 30.8 (25-35) | 6 (-7 to 63) |
| 30.9 (22-40) | 31 Osteoarthritis | 32 Hypertensive heart disease | 32.3 (27-37) | 3 (-9 to 19) |
| 31.0 (23-39) | 32 Schizophrenia | 33 HIV/AIDS | 35.2 (32-39) | -61 (-66 to -55) |

Abbreviations: UI, uncertainty interval; HIV, human immunodeficiency virus.
may consume less sodium. Yet, most studies used in the metaanalyses of each dietary component controlled for BMI and other key behaviors such as physical activity and tobacco use. Also, the individual dietary component effect sizes are consistent with overall dietary pattern studies; for example, the recent PREDIMED ${ }^{54}$ trial reported significant benefits of healthful diet patterns on clinical cardiovascular events, and the magnitudes of benefits in that trial are highly consistent with our predicted risk estimates (D. M., unpublished data, March 2013). Furthermore, randomized feeding study results are consistent with significant benefits to blood pressure and cholesterol. ${ }^{55,56}$ Another limitation of the evidence on diet is that many studies have limited periods of follow-up, whereas the chronic diseases related to diet develop over decades. To the extent that some diet components may also contribute to energy imbalance and ultimately to elevated BMI, the full relationships between diet and health outcomes are not captured in our analysis of the composition of diet. ${ }^{57}$

Between 1990 and 2010, DALYs related to elevated BMI independent of diet composition increased by $45 \%$. Detailed analysis of BMI suggests that increases are even larger in
some parts of the United States, such as the Southeast. These same assessments suggest that levels of physical activity may be improving at the same time that overweight and obesity rates are increasing. ${ }^{58}$ Rising obesity rates are a potentially unique challenge for the United States and the world. There is some controversy, however, surrounding the BMI level corresponding to the lowest relative risks. Flegal et al ${ }^{59}$ reported a systematic review of published studies and argued that excess mortality is only observed for a BMI over 35 . However, this study did not incorporate the standardized analyses based on the large pooling projects that were the basis for the GBD 2010, which included more than 11 million person-years of observation. ${ }^{60-62}$ These pooling studies reported a stronger and more consistent relationship across a range of BMI values than did the Flegal metaanalysis, with excess mortality increasing steadily beginning at a BMI of 21.0 to 23.0. ${ }^{63-65}$ The risks of diet composition, physical inactivity and low activity, and high BMI are highly intertwined; currently, more effective strategies ${ }^{66,67}$ are available for modifying diet and physical inactivity than for lowering high BMI.

Figure 3. Number of Deaths and Percentage of Disability-Adjusted Life-Years Related to the 17 Leading Risk Factors in the United States in 2010 for Both Sexes Combined


Diabetes, Kidney Disease, and Neurological Disorders The increase in disease burden from diabetes and CKD is particularly noteworthy. We estimate in this study that in 2010, $23.5 \%$ of CKD and $76.0 \%$ of diabetes DALYs were related to BMI, increases from $18.1 \%$ and $64.3 \%$ in 1990, respectively. The increase in CKD-related mortality was larger than the increase in mortality related to diabetes, which suggests that other causes of CKD may also be increasing. Given the costs associated with long-term management of diabetes and CKD, these trends are likely to continue to increase health costs. ${ }^{68}$ Improved survival among persons with diabetes by effective management of major cardiovascular and renal risks such as hyperglycemia, hypertension, and high cholesterol may improve overall population health but will likely increase costs as well.

Recent data indicate improvements in the quality of care for diabetes. ${ }^{69}$ Evidence that diabetes can be substantially prevented or postponed in people with prediabetes through focused lifestyle or drug therapy has accumulated over the past few years. ${ }^{70}$

Neurological conditions increased from 2.0\% of DALYs in 1990 to $3.0 \%$ in 2010. Both Alzheimer disease and Parkinson disease are associated with large increases in DALYs. Although the increase in Alzheimer disease may be confounded by changes in ascertainment and coding practice, these increases suggest an important trend. Migraine and epilepsy are also ranked 14th and 30th as diseases contributing to YLDs, respectively. Both aging and increasing agestandardized prevalence rates are contributing to a growing challenge of neurological disease.

Table 3. Age-Standardized Rates of Death, Years of Life Lost Due to Premature Mortality (YLL), and Years Lived With Disability (YLD) for Organisation for Economic Co-operation and Development Countries in 1990 and 2010, Both Sexes Combined, With 95\% Uncertainty Intervals

| Country | Age-Standardized Death Rate (per 100 000) |  |  |  | Age-Standardized YLL Rate (per 100 000) |  |  |  | Age-Standardized YLD Rate (per 100 000) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1990 |  | 2010 |  | 1990 |  | 2010 |  | 1990 |  | 2010 |  |
|  | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank |
| United States | $\begin{gathered} \hline 639 \\ (637-642) \end{gathered}$ | $\begin{gathered} 18 \\ (16-19) \end{gathered}$ | $\begin{gathered} 516 \\ (513-519) \end{gathered}$ | $\begin{gathered} 27 \\ (27-27) \end{gathered}$ | $\begin{aligned} & 15130 \\ & (14957- \\ & 15283) \end{aligned}$ | $\begin{gathered} 23 \\ (23-23) \end{gathered}$ | $\begin{aligned} & 11447 \\ & (11312- \\ & 11630) \end{aligned}$ | $\begin{gathered} 28 \\ (28-28) \end{gathered}$ | $\begin{aligned} & 10503 \\ & (8753- \\ & 12449) \end{aligned}$ | $\begin{gathered} 5 \\ (3-13) \end{gathered}$ | $\begin{aligned} & 10509 \\ & (8803- \\ & 12375) \end{aligned}$ | $\begin{gathered} 6 \\ (5-15) \end{gathered}$ |
| Australia | $\begin{gathered} 568 \\ (564-571) \end{gathered}$ | $\begin{gathered} 9 \\ (9-9) \end{gathered}$ | $\begin{gathered} 389 \\ (386-393) \end{gathered}$ | $\begin{gathered} 4 \\ (4-5) \end{gathered}$ | $\begin{aligned} & 12381 \\ & (12213- \\ & 12520) \end{aligned}$ | $\begin{gathered} 10 \\ (9-10) \end{gathered}$ | $\begin{gathered} 7722 \\ (7610- \\ 7897) \end{gathered}$ | $\begin{gathered} 8 \\ (6-8) \end{gathered}$ | $\begin{aligned} & 11153 \\ & (9223- \\ & 13293) \end{aligned}$ | $\begin{gathered} 18 \\ (9-29) \end{gathered}$ | $\begin{aligned} & 10979 \\ & (9088- \\ & 13165) \end{aligned}$ | $\begin{gathered} 14 \\ (8-26) \end{gathered}$ |
| Austria | $\begin{gathered} 622 \\ (616-626) \end{gathered}$ | $\begin{gathered} 15 \\ (15-15) \end{gathered}$ | $\begin{gathered} 418 \\ (414-424) \end{gathered}$ | $\begin{gathered} 11 \\ (11-12) \end{gathered}$ | $\begin{aligned} & 13732 \\ & (13482- \\ & 13905) \end{aligned}$ | $\begin{gathered} 16 \\ (16-16) \end{gathered}$ | $\begin{gathered} 8401 \\ (8290- \\ 8596) \end{gathered}$ | $\begin{gathered} 11 \\ (11-12) \end{gathered}$ | $\begin{aligned} & 11052 \\ & (8996- \\ & 13572) \end{aligned}$ | $\begin{gathered} 14 \\ (3-33) \end{gathered}$ | $\begin{aligned} & 11381 \\ & (9227- \\ & 13801) \end{aligned}$ | $\begin{gathered} 26 \\ (6-34) \end{gathered}$ |
| Belgium | $\begin{gathered} 615 \\ (610-619) \end{gathered}$ | $\begin{gathered} 14 \\ (14-14) \end{gathered}$ | $\begin{gathered} 460 \\ (453-469) \end{gathered}$ | $\begin{gathered} 21 \\ (20-22) \end{gathered}$ | $\begin{aligned} & 13458 \\ & (13269- \\ & 13603) \end{aligned}$ | $\begin{gathered} 15 \\ (14-15) \end{gathered}$ | $\begin{gathered} 9381 \\ (9216- \\ 9625) \end{gathered}$ | $\begin{gathered} 22 \\ (22-24) \end{gathered}$ | $\begin{aligned} & 11119 \\ & (9183- \\ & 13337) \end{aligned}$ | $\begin{gathered} 16 \\ (7-29) \end{gathered}$ | $\begin{aligned} & 10933 \\ & (9042- \\ & 13071) \end{aligned}$ | $\begin{gathered} 13 \\ (6-28) \end{gathered}$ |
| Canada | $\begin{gathered} 558 \\ (554-561) \end{gathered}$ | $\begin{gathered} 7 \\ (6-7) \end{gathered}$ | $\begin{gathered} 422 \\ (418-427) \end{gathered}$ | $\begin{gathered} 12 \\ (11-13) \end{gathered}$ | $\begin{aligned} & 12079 \\ & (11923- \\ & 12203) \end{aligned}$ | $\begin{gathered} 7 \\ (6-8) \end{gathered}$ | $\begin{gathered} 8546 \\ (8429- \\ 8714) \end{gathered}$ | $\begin{gathered} 14 \\ (12-16) \end{gathered}$ | $\begin{aligned} & 10806 \\ & (8988- \\ & 12878) \end{aligned}$ | $\begin{gathered} 8 \\ (4-22) \end{gathered}$ | $\begin{aligned} & 10845 \\ & (9035- \\ & 12854) \end{aligned}$ | $\begin{gathered} 11 \\ (5-25) \end{gathered}$ |
| Chile | $\begin{gathered} 760 \\ (752-767) \end{gathered}$ | $\begin{gathered} 27 \\ (26-27) \end{gathered}$ | $\begin{gathered} 490 \\ (482-500) \end{gathered}$ | $\begin{gathered} 25 \\ (25-25) \end{gathered}$ | $\begin{aligned} & 18210 \\ & (17880- \\ & 18511) \end{aligned}$ | $\begin{gathered} 26 \\ (26-26) \end{gathered}$ | $\begin{aligned} & 11136 \\ & (10920- \\ & 11448) \end{aligned}$ | $\begin{gathered} 27 \\ (26-27) \end{gathered}$ | $\begin{aligned} & 11185 \\ & (9275- \\ & 13408) \end{aligned}$ | $\stackrel{20}{20}$ | $\begin{aligned} & 10407 \\ & (8562- \\ & 12391) \end{aligned}$ | $\begin{gathered} 5 \\ (3-23) \end{gathered}$ |
| Czech Republic | $\begin{gathered} 876 \\ (868-880) \end{gathered}$ | $\begin{gathered} 30 \\ (30-30) \end{gathered}$ | $\begin{gathered} 548 \\ (545-554) \end{gathered}$ | $\begin{gathered} 28 \\ (28-28) \end{gathered}$ | $\begin{aligned} & 19311 \\ & (18959- \\ & 19521) \end{aligned}$ | $\begin{gathered} 28 \\ (28-28) \end{gathered}$ | $\begin{aligned} & 10997 \\ & (10894- \\ & 11188) \end{aligned}$ | $\begin{gathered} 26 \\ (26-27) \end{gathered}$ | $\begin{aligned} & 11015 \\ & (9009- \\ & 13254) \end{aligned}$ | $\begin{gathered} 10 \\ (5-30) \end{gathered}$ | $\begin{aligned} & 10759 \\ & (8799- \\ & 12879) \end{aligned}$ | $\begin{gathered} 7 \\ (5-27) \end{gathered}$ |
| Denmark | $\begin{gathered} 656 \\ (650-660) \end{gathered}$ | $\begin{gathered} 22 \\ (21-22) \end{gathered}$ | $\begin{gathered} 504 \\ (499-510) \end{gathered}$ | $\begin{gathered} 26 \\ (26-26) \end{gathered}$ | $\begin{aligned} & 14383 \\ & (14129- \\ & 14547) \end{aligned}$ | $\begin{gathered} 20 \\ (18-21) \end{gathered}$ | $\begin{gathered} 9592 \\ (9480- \\ 9775) \end{gathered}$ | $\begin{gathered} 25 \\ (24-25) \end{gathered}$ | $\begin{aligned} & 11209 \\ & (9240- \\ & 13542) \end{aligned}$ | $\begin{gathered} 21 \\ (7-31) \end{gathered}$ | $\begin{aligned} & 11456 \\ & (9449- \\ & 13662) \end{aligned}$ | $\begin{gathered} 28 \\ (14-33) \end{gathered}$ |
| Estonia | $\begin{gathered} 910 \\ (897-918) \end{gathered}$ | $\begin{gathered} 32 \\ (32-33) \end{gathered}$ | $\begin{gathered} 603 \\ (595-617) \end{gathered}$ | $\begin{gathered} 30 \\ (30-32) \end{gathered}$ | $\begin{array}{r} 23443 \\ (22786- \\ 23925) \end{array}$ | $\begin{gathered} 32 \\ (31-33) \end{gathered}$ | $\begin{gathered} 13954 \\ (13651- \\ 14490) \end{gathered}$ | $\begin{gathered} 31 \\ (30-31) \end{gathered}$ | $\begin{aligned} & 11129 \\ & (9204- \\ & 13286) \end{aligned}$ | $\begin{gathered} 17 \\ (5-31) \end{gathered}$ | $\begin{aligned} & 11165 \\ & (9237- \\ & 13205) \end{aligned}$ | $\begin{gathered} 22 \\ (7-32) \end{gathered}$ |
| Finland | $\begin{gathered} 655 \\ (648-660) \end{gathered}$ | $\begin{gathered} 21 \\ (21-22) \end{gathered}$ | $\begin{gathered} 437 \\ (433-443) \end{gathered}$ | $\begin{gathered} 17 \\ (16-17) \end{gathered}$ | $\begin{aligned} & 14467 \\ & (14220- \\ & 14614) \end{aligned}$ | $\begin{gathered} 21 \\ (20-22) \end{gathered}$ | $\begin{gathered} 9050 \\ (8941- \\ 9221) \end{gathered}$ | $\begin{gathered} 21 \\ (20-21) \end{gathered}$ | $\begin{aligned} & 11092 \\ & (9158- \\ & 13200) \end{aligned}$ | $\begin{gathered} 15 \\ (8-28) \end{gathered}$ | $\begin{aligned} & 11248 \\ & (9355- \\ & 13368) \end{aligned}$ | $\begin{gathered} 25 \\ (11-31) \end{gathered}$ |
| France | $\begin{gathered} 549 \\ (545-553) \end{gathered}$ | $\begin{gathered} 5 \\ (4-5) \end{gathered}$ | $\begin{gathered} 408 \\ (403-416) \end{gathered}$ | $\begin{gathered} 9 \\ (8-9) \end{gathered}$ | $\begin{aligned} & 12717 \\ & (12535- \\ & 12858) \end{aligned}$ | $\begin{gathered} 12 \\ (11-13) \end{gathered}$ | $\begin{gathered} 8666 \\ (8516- \\ 8912) \end{gathered}$ | $\begin{gathered} 16 \\ (14-17) \end{gathered}$ | $\begin{aligned} & 11358 \\ & (9418- \\ & 13475) \end{aligned}$ | $\begin{gathered} 27 \\ (12-31) \end{gathered}$ | $\begin{aligned} & 11194 \\ & (9279- \\ & 13307) \end{aligned}$ | $\begin{gathered} 23 \\ (10-30) \end{gathered}$ |
| Germany | $\begin{gathered} 644 \\ (641-646) \end{gathered}$ | $\begin{gathered} 20 \\ (19-20) \end{gathered}$ | $\begin{gathered} 433 \\ (429-440) \end{gathered}$ | $\begin{gathered} 16 \\ (15-16) \end{gathered}$ | $\begin{gathered} 14032 \\ (13863- \\ 14171) \end{gathered}$ | $\begin{gathered} 17 \\ (17-18) \end{gathered}$ | $\begin{gathered} 8512 \\ (8383- \\ 8739) \end{gathered}$ | $\begin{gathered} 13 \\ (12-14) \end{gathered}$ | $\begin{aligned} & 11165 \\ & (9271- \\ & 13253) \end{aligned}$ | $\begin{gathered} 19 \\ (10-28) \end{gathered}$ | $\begin{aligned} & 11015 \\ & (9177- \\ & 13070) \end{aligned}$ | $\begin{gathered} 15 \\ (9-26) \end{gathered}$ |
| Greece | $\begin{gathered} 573 \\ (569-577) \end{gathered}$ | $\begin{gathered} 11 \\ (10-11) \end{gathered}$ | $\begin{gathered} 465 \\ (458-472) \end{gathered}$ | $\begin{gathered} 23 \\ (21-24) \end{gathered}$ | $\begin{gathered} 12011 \\ (11801- \\ 12187) \end{gathered}$ | $\begin{gathered} 6 \\ (6-7) \end{gathered}$ | $\begin{gathered} 8806 \\ (8654- \\ 9000) \end{gathered}$ | $\begin{gathered} 18 \\ (16-19) \end{gathered}$ | $\begin{aligned} & 11040 \\ & (8964- \\ & 13224) \end{aligned}$ | $\begin{gathered} 13 \\ (5-31) \end{gathered}$ | $\begin{aligned} & 10809 \\ & (8962- \\ & 12947) \end{aligned}$ | $\begin{gathered} 9 \\ (5-28) \end{gathered}$ |
| Hungary | $\begin{gathered} 970 \\ (963-974) \end{gathered}$ | $\begin{gathered} 34 \\ (33-34) \end{gathered}$ | $\begin{gathered} 694 \\ (691-700) \end{gathered}$ | $\begin{gathered} 34 \\ (34-34) \end{gathered}$ | $\begin{array}{r} 23806 \\ (23476- \\ 24044) \end{array}$ | $\begin{gathered} 33 \\ (32-33) \end{gathered}$ | $\begin{gathered} 15271 \\ (15147- \\ 15468) \end{gathered}$ | $\begin{gathered} 32 \\ (32-32) \end{gathered}$ | $\begin{aligned} & 11665 \\ & (9624- \\ & 13981) \end{aligned}$ | $\begin{gathered} 31 \\ (15-33) \end{gathered}$ | $\begin{aligned} & 11589 \\ & (9569- \\ & 13866) \end{aligned}$ | $\begin{gathered} 32 \\ (17-33) \end{gathered}$ |
| Iceland | $\begin{gathered} 548 \\ (533-558) \end{gathered}$ | $\begin{gathered} 4 \\ (3-6) \end{gathered}$ | $\begin{gathered} 365 \\ (356-376) \end{gathered}$ | $\begin{gathered} 2 \\ (2-3) \end{gathered}$ | $\begin{aligned} & 11310 \\ & (10897- \\ & 11575) \end{aligned}$ | $\begin{gathered} 3 \\ (2-3) \end{gathered}$ | $\begin{gathered} 6675 \\ (6482- \\ 7016) \end{gathered}$ | $\begin{gathered} 1 \\ (1-2) \end{gathered}$ | $\begin{aligned} & 10763 \\ & (8808- \\ & 12855) \end{aligned}$ | $\begin{gathered} 7 \\ (3-26) \end{gathered}$ | $\begin{aligned} & 11108 \\ & (9158- \\ & 13286) \end{aligned}$ | $\begin{gathered} 21 \\ (6-32) \end{gathered}$ |
| Ireland | $\begin{gathered} 692 \\ (683-698) \end{gathered}$ | $\begin{gathered} 24 \\ (24-24) \end{gathered}$ | $\begin{gathered} 453 \\ (447-459) \end{gathered}$ | $\begin{gathered} 19 \\ (19-20) \end{gathered}$ | $\begin{gathered} 14298 \\ (14048- \\ 14491) \end{gathered}$ | $\begin{gathered} 19 \\ (18-20) \end{gathered}$ | $\begin{gathered} 8764 \\ (8662- \\ 8936) \end{gathered}$ | $\begin{gathered} 17 \\ (16-18) \end{gathered}$ | $\begin{aligned} & 11024 \\ & (8858- \\ & 13314) \end{aligned}$ | $\begin{gathered} 11 \\ (3-33) \end{gathered}$ | $\begin{aligned} & 11138 \\ & (9042- \\ & 13602) \end{aligned}$ | $\begin{gathered} 19 \\ (5-34) \end{gathered}$ |
| Israel | $\begin{gathered} 584 \\ (577-588) \end{gathered}$ | $\begin{gathered} 13 \\ (12-13) \end{gathered}$ | $\begin{gathered} 406 \\ (401-409) \end{gathered}$ | $\begin{gathered} 8 \\ (7-9) \end{gathered}$ | $\begin{gathered} 12760 \\ (12511- \\ 12962) \end{gathered}$ | $\begin{gathered} 13 \\ (11-13) \end{gathered}$ | $\begin{gathered} 7682 \\ (7578- \\ 7815) \end{gathered}$ | $\begin{gathered} 6 \\ (6-8) \end{gathered}$ | $\begin{aligned} & 10877 \\ & (8950- \\ & 12984) \end{aligned}$ | $\begin{gathered} 9 \\ (5-25) \end{gathered}$ | $\begin{aligned} & 10792 \\ & (8891- \\ & 12912) \end{aligned}$ | $\begin{gathered} 8 \\ (5-25) \end{gathered}$ |
| Italy | $\begin{gathered} 561 \\ (558-563) \end{gathered}$ | $\begin{gathered} 8 \\ (8-8) \end{gathered}$ | $\begin{gathered} 389 \\ (386-396) \end{gathered}$ | $\begin{gathered} 5 \\ (4-5) \end{gathered}$ | $\begin{gathered} 12202 \\ (12053- \\ 12330) \end{gathered}$ | $\begin{gathered} 8 \\ (8-9) \end{gathered}$ | $\begin{array}{r} 7485 \\ (7359- \\ 7703) \end{array}$ | $\begin{gathered} 5 \\ (5-5) \end{gathered}$ | $\begin{aligned} & 11038 \\ & (9150- \\ & 13174) \end{aligned}$ | $\begin{gathered} 12 \\ (7-27) \end{gathered}$ | $\begin{aligned} & 10907 \\ & (9081- \\ & 12895) \end{aligned}$ | $\begin{gathered} 12 \\ (7-25) \end{gathered}$ |
| Japan | $\begin{gathered} 469 \\ (466-471) \end{gathered}$ | $\begin{gathered} 1 \\ (1-1) \end{gathered}$ | $\begin{gathered} 352 \\ (350-356) \end{gathered}$ | $\begin{gathered} 1 \\ (1-1) \end{gathered}$ | $\begin{gathered} 9658 \\ (9552- \\ 9750) \end{gathered}$ | $\begin{gathered} 1 \\ (1-1) \end{gathered}$ | $\begin{gathered} 6827 \\ (6761- \\ 6939) \end{gathered}$ | $\begin{gathered} 2 \\ (1-2) \end{gathered}$ | $\begin{gathered} 9406 \\ (7794- \\ 11361) \end{gathered}$ | $\begin{gathered} 1 \\ (1-2) \end{gathered}$ | $\begin{gathered} 9094 \\ (7465- \\ 10904) \end{gathered}$ | $\begin{gathered} 1 \\ (1-3) \end{gathered}$ |
| Luxembourg | $\begin{gathered} 641 \\ (629-649) \end{gathered}$ | $\begin{gathered} 19 \\ (16-20) \end{gathered}$ | $\begin{gathered} 432 \\ (423-445) \end{gathered}$ | $\begin{gathered} 15 \\ (14-17) \end{gathered}$ | $\begin{array}{r} 14255 \\ (13882- \\ 14510) \end{array}$ | $\begin{gathered} 18 \\ (17-20) \end{gathered}$ | $\begin{gathered} 8484 \\ (8282- \\ 8845) \end{gathered}$ | $\begin{gathered} 12 \\ (11-15) \end{gathered}$ | $\begin{aligned} & 11370 \\ & (9100- \\ & 13868) \end{aligned}$ | $\begin{gathered} 23 \\ (5-34) \end{gathered}$ | $\begin{aligned} & 11683 \\ & (9503- \\ & 14350) \end{aligned}$ | $\begin{gathered} 30 \\ (8-34) \end{gathered}$ |
| Mexico | $\begin{gathered} 740 \\ (732-749) \end{gathered}$ | $\begin{gathered} 25 \\ (25-25) \end{gathered}$ | $\begin{gathered} 604 \\ (599-609) \end{gathered}$ | $\begin{gathered} 31 \\ (30-32) \end{gathered}$ | $\begin{array}{r} 22775 \\ (22171- \\ 23502) \end{array}$ | $\begin{gathered} 31 \\ (31-32) \end{gathered}$ | $\begin{array}{r} 15658 \\ (15365- \\ 15976) \end{array}$ | $\begin{gathered} 33 \\ (33-34) \end{gathered}$ | $\begin{aligned} & 10092 \\ & (8414- \\ & 12094) \end{aligned}$ | $\begin{gathered} 2 \\ (2-8) \end{gathered}$ | $\begin{gathered} 9364 \\ (7762- \\ 11245) \end{gathered}$ | $\begin{gathered} 2 \\ (1-3) \end{gathered}$ |
| Netherlands | $\begin{gathered} 572 \\ (567-575) \end{gathered}$ | $\begin{gathered} 10 \\ (10-11) \end{gathered}$ | $\begin{gathered} 426 \\ (422-430) \end{gathered}$ | $\begin{gathered} 14 \\ (13-15) \end{gathered}$ | $\begin{gathered} 11847 \\ (11666- \\ 11974) \end{gathered}$ | $\begin{gathered} 5 \\ (4-5) \end{gathered}$ | $\begin{gathered} 7988 \\ (7898- \\ 8127) \end{gathered}$ | $\begin{gathered} 10 \\ (9-10) \end{gathered}$ | $\begin{aligned} & 11355 \\ & (9498- \\ & 13387) \end{aligned}$ | $\begin{gathered} 28 \\ (13-31) \end{gathered}$ | $\begin{aligned} & 11492 \\ & (9624- \\ & 13445) \end{aligned}$ | $\begin{gathered} 31 \\ (17-33) \end{gathered}$ |

Table 3. Age-Standardized Rates of Death, Years of Life Lost Due to Premature Mortality (YLL), and Years Lived With Disability (YLD) for Organisation for Economic Co-operation and Development Countries in 1990 and 2010, Both Sexes Combined, With 95\% Uncertainty Intervals (continued)

| Country | Age-Standardized Death Rate (per 100 000) |  |  |  | Age-Standardized YLL Rate (per 100 000) |  |  |  | Age-Standardized YLD Rate (per 100 000) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1990 |  | 2010 |  | 1990 |  | 2010 |  | 1990 |  | 2010 |  |
|  | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank | Rate | Rank |
| New Zealand | $\begin{gathered} 637 \\ (629-641) \end{gathered}$ | $\begin{gathered} 16 \\ (16-18) \end{gathered}$ | $\begin{gathered} \hline 413 \\ (408-420) \end{gathered}$ | $\begin{gathered} 10 \\ (10-10) \end{gathered}$ | $\begin{aligned} & 14523 \\ & (14230- \\ & 14722) \end{aligned}$ | $\begin{gathered} 22 \\ (20-22) \end{gathered}$ | $\begin{gathered} \hline 8611 \\ (8443- \\ 8863) \end{gathered}$ | $\begin{gathered} 15 \\ (13-17) \end{gathered}$ | $\begin{aligned} & 11247 \\ & (9340- \\ & 13337) \end{aligned}$ | $\begin{gathered} 22 \\ (9-30) \end{gathered}$ | $\begin{aligned} & 11067 \\ & (9143- \\ & 13117) \end{aligned}$ | $\begin{gathered} 17 \\ (8-28) \end{gathered}$ |
| Norway | $\begin{gathered} 580 \\ (572-584) \end{gathered}$ | $\begin{gathered} 12 \\ (12-13) \end{gathered}$ | $\begin{gathered} 422 \\ (418-429) \end{gathered}$ | $\begin{gathered} 13 \\ (12-14) \end{gathered}$ | $\begin{gathered} 12291 \\ (12041- \\ 12495) \end{gathered}$ | $\begin{gathered} 9 \\ (8-10) \end{gathered}$ | $\begin{gathered} 7904 \\ (7793- \\ 8095) \end{gathered}$ | $\begin{gathered} 9 \\ (9-10) \end{gathered}$ | $\begin{aligned} & 12365 \\ & (10177- \\ & 14638) \end{aligned}$ | $\begin{gathered} 33 \\ (30-34) \end{gathered}$ | $\begin{aligned} & 12329 \\ & (10248- \\ & 14634) \end{aligned}$ | $\begin{gathered} 34 \\ (30-34) \end{gathered}$ |
| Poland | $\begin{gathered} 872 \\ (867-876) \end{gathered}$ | $\begin{gathered} 29 \\ (29-29) \end{gathered}$ | $\begin{gathered} 589 \\ (586-592) \end{gathered}$ | $\begin{gathered} 29 \\ (29-30) \end{gathered}$ | $\begin{array}{r} 21136 \\ (20820- \\ 21366) \end{array}$ | $\begin{gathered} 30 \\ (30-30) \end{gathered}$ | $\begin{aligned} & 13059 \\ & (12965- \\ & 13213) \end{aligned}$ | $\begin{gathered} 29 \\ (29-29) \end{gathered}$ | $\begin{aligned} & 11652 \\ & (9519- \\ & 14326) \end{aligned}$ | $\begin{gathered} 30 \\ (9-34) \end{gathered}$ | $\begin{aligned} & 11401 \\ & (9348- \\ & 14029) \end{aligned}$ | $\begin{gathered} 27 \\ (6-34) \end{gathered}$ |
| Portugal | $\begin{gathered} 679 \\ (672-683) \end{gathered}$ | $\begin{gathered} 23 \\ (23-23) \end{gathered}$ | $\begin{gathered} 468 \\ (464-474) \end{gathered}$ | $\begin{gathered} 24 \\ (23-24) \end{gathered}$ | $\begin{aligned} & 16152 \\ & (15800- \\ & 16415) \end{aligned}$ | $\begin{gathered} 24 \\ (24-24) \end{gathered}$ | $\begin{gathered} 9407 \\ (9310- \\ 9602) \end{gathered}$ | $\begin{gathered} 23 \\ (22-24) \end{gathered}$ | $\begin{aligned} & 11409 \\ & (9250- \\ & 13971) \end{aligned}$ | $\begin{gathered} 24 \\ (5-34) \end{gathered}$ | $\begin{aligned} & 11123 \\ & (9002- \\ & 13600) \end{aligned}$ | $\begin{gathered} 18 \\ (5-34) \end{gathered}$ |
| Slovakia | $\begin{gathered} 893 \\ (885-898) \end{gathered}$ | $\begin{gathered} 31 \\ (31-31) \end{gathered}$ | $\begin{gathered} 652 \\ (647-658) \end{gathered}$ | $\begin{gathered} 33 \\ (32-33) \end{gathered}$ | $\begin{array}{r} 20667 \\ (20373- \\ 20880) \end{array}$ | $\begin{gathered} 29 \\ (29-29) \end{gathered}$ | $\begin{array}{r} 13779 \\ (13640- \\ 13936) \end{array}$ | $\begin{gathered} 30 \\ (30-31) \end{gathered}$ | $\begin{aligned} & 11905 \\ & (9872- \\ & 14185) \end{aligned}$ | $\begin{gathered} 32 \\ (16-34) \end{gathered}$ | $\begin{aligned} & 11042 \\ & (9109- \\ & 13100) \end{aligned}$ | $\begin{gathered} 16 \\ (6-31) \end{gathered}$ |
| Slovenia | $\begin{gathered} 760 \\ (749-767) \end{gathered}$ | $\begin{gathered} 26 \\ (26-27) \end{gathered}$ | $\begin{gathered} 465 \\ (459-474) \end{gathered}$ | $\begin{gathered} 22 \\ (21-24) \end{gathered}$ | $\begin{gathered} 17330 \\ (16946- \\ 17558) \end{gathered}$ | $\begin{gathered} 25 \\ (25-25) \end{gathered}$ | $\begin{gathered} 9491 \\ (9325- \\ 9793) \end{gathered}$ | $\begin{gathered} 24 \\ (23-25) \end{gathered}$ | $\begin{aligned} & 11410 \\ & (9512- \\ & 13844) \end{aligned}$ | $\begin{gathered} 26 \\ (8-32) \end{gathered}$ | $\begin{aligned} & 11095 \\ & (9093- \\ & 13276) \end{aligned}$ | $\begin{gathered} 20 \\ (6-32) \end{gathered}$ |
| South Korea | $\begin{gathered} 813 \\ (802-822) \end{gathered}$ | $\begin{gathered} 28 \\ (28-28) \end{gathered}$ | $\begin{gathered} 447 \\ (441-452) \end{gathered}$ | $\begin{gathered} 18 \\ (18-18) \end{gathered}$ | $\begin{array}{r} 18830 \\ (18158- \\ 19318) \end{array}$ | $\begin{gathered} 27 \\ (27-27) \end{gathered}$ | $\begin{aligned} & 8941 \\ & (8801- \\ & 9093) \end{aligned}$ | $\begin{gathered} 19 \\ (18-21) \end{gathered}$ | $\begin{aligned} & 10074 \\ & (8289- \\ & 12073) \end{aligned}$ | $\begin{gathered} 4 \\ (1-12) \end{gathered}$ | $\begin{gathered} 9575 \\ (7888- \\ 11559) \end{gathered}$ | $\begin{gathered} 3 \\ (1-5) \end{gathered}$ |
| Spain | $\begin{gathered} 557 \\ (553-560) \end{gathered}$ | $\begin{gathered} 6 \\ (5-7) \end{gathered}$ | $\begin{gathered} 393 \\ (389-399) \end{gathered}$ | $\begin{gathered} 6 \\ (6-6) \end{gathered}$ | $\begin{aligned} & 12630 \\ & (12423- \\ & 12786) \end{aligned}$ | $\begin{gathered} 11 \\ (11-12) \end{gathered}$ | $\begin{array}{r} 7694 \\ (7565- \\ 7909) \end{array}$ | $\begin{gathered} 7 \\ (6-8) \end{gathered}$ | $\begin{aligned} & 10136 \\ & (8452- \\ & 12010) \end{aligned}$ | $\begin{gathered} 3 \\ (2-7) \end{gathered}$ | $\begin{aligned} & 10068 \\ & (8399- \\ & 11965) \end{aligned}$ | $\begin{gathered} 4 \\ (3-7) \end{gathered}$ |
| Sweden | $\begin{gathered} 539 \\ (535-543) \end{gathered}$ | $\begin{gathered} 3 \\ (3-4) \end{gathered}$ | $\begin{gathered} 403 \\ (400-408) \end{gathered}$ | $\begin{gathered} 7 \\ (7-8) \end{gathered}$ | $\begin{aligned} & 11196 \\ & (11006- \\ & 11329) \end{aligned}$ | $\begin{gathered} 2 \\ (2-3) \end{gathered}$ | $\begin{gathered} 7296 \\ (7208- \\ 7453) \end{gathered}$ | $\begin{gathered} 4 \\ (4-4) \end{gathered}$ | $\begin{aligned} & 11378 \\ & (9453- \\ & 13414) \end{aligned}$ | $\begin{gathered} 25 \\ (10-32) \end{gathered}$ | $\begin{aligned} & 11250 \\ & (9236- \\ & 13372) \end{aligned}$ | $\begin{gathered} 24 \\ (9-32) \end{gathered}$ |
| Switzerland | $\begin{gathered} 532 \\ (526-536) \end{gathered}$ | $\begin{gathered} 2 \\ (2-2) \end{gathered}$ | $\begin{gathered} 369 \\ (366-374) \end{gathered}$ | $\begin{gathered} 3 \\ (2-3) \end{gathered}$ | $\begin{gathered} 11825 \\ (11568- \\ 11981) \end{gathered}$ | $\begin{gathered} 4 \\ (4-5) \end{gathered}$ | $\begin{gathered} 7071 \\ (6972- \\ 7253) \end{gathered}$ | $\begin{gathered} 3 \\ (3-3) \end{gathered}$ | $\begin{aligned} & 10663 \\ & (8689- \\ & 12738) \end{aligned}$ | $\begin{gathered} 6 \\ (3-25) \end{gathered}$ | $\begin{aligned} & 10807 \\ & (8883- \\ & 12902) \end{aligned}$ | $\begin{gathered} 10 \\ (5-30) \end{gathered}$ |
| Turkey | $\begin{gathered} 942 \\ (895-980) \end{gathered}$ | $\begin{gathered} 33 \\ (32-34) \end{gathered}$ | $\begin{gathered} 628 \\ (584-660) \end{gathered}$ | $\begin{gathered} 32 \\ (29-33) \end{gathered}$ | $\begin{array}{r} 30025 \\ (28350- \\ 31541) \end{array}$ | $\begin{gathered} 34 \\ (34-34) \end{gathered}$ | $\begin{array}{r} 16760 \\ (15331- \\ 18071) \end{array}$ | $\begin{gathered} 34 \\ (33-34) \end{gathered}$ | $\begin{aligned} & 12442 \\ & (10380- \\ & 14783) \end{aligned}$ | $\begin{gathered} 34 \\ (30-34) \end{gathered}$ | 11885 (989514020 ) | $\begin{gathered} 33 \\ (24-34) \end{gathered}$ |
| United Kingdom | $\begin{gathered} 638 \\ (634-642) \end{gathered}$ | $\begin{gathered} 17 \\ (16-19) \end{gathered}$ | $\begin{gathered} 455 \\ (452-458) \end{gathered}$ | $\begin{gathered} 20 \\ (19-21) \end{gathered}$ | $\begin{aligned} & 13452 \\ & (13296- \\ & 13581) \end{aligned}$ | $\begin{gathered} 14 \\ (14-15) \end{gathered}$ | $\begin{gathered} 8949 \\ (8871- \\ 9052) \end{gathered}$ | $\begin{gathered} 20 \\ (19-20) \end{gathered}$ | $\begin{aligned} & 11453 \\ & (9466- \\ & 13603) \end{aligned}$ | $\begin{gathered} 29 \\ (16-31) \end{gathered}$ | $\begin{aligned} & 11435 \\ & (9482- \\ & 13569) \end{aligned}$ | $\begin{gathered} 29 \\ (18-32) \end{gathered}$ |

## Road Injury

Road injury YLLs declined by 33\% from 1990 to 2010. Nevertheless, road injuries remained the second and fifth disease or injury contributing to YLLs for males and females, respectively, in 2010. Age-standardized YLLs related to road injuries in the United States are exceeded only by those of South Korea, Greece, and Mexico. Compared with Sweden and Iceland, which have the lowest road injury death rates in the OECD, mortality from this cause in the United States is 3 -fold greater; although exposure in terms of miles driven per capita may be higher in the United States. Sweden is pursuing Vision Zero, which seeks to eliminate all road injury deaths through a range of interventions. ${ }^{71}$ Interventions to reduce road injury deaths work. In 1990, age-standardized YLL rates from road injury in Spain were nearly identical to those in the United States; concerted public action, ${ }^{72}$ however, has led to a $62 \%$ decline in Spain over the past 20 years. Given the critical role of road injury as a contributor to US premature mortality, a more concerted intervention approach, drawing on lessons from other countries, would seem to be a key US public health priority. ${ }^{73}$ Such interventions include more stringent antidrunk driving measures, such as ignition interlocks for persons convicted of driving while intoxicated, increased use of sobriety checkpoints, and greater enforcement of underage
drinking laws; increased use of motorcycle helmets; increased enactment of primary seat belt laws together with enhanced enforcement programs; and greater use of graduated driver licensing for teen drivers. ${ }^{74}$

## Comparison With OECD Countries

From 1990 to 2010, improvements in population health in the United States did not keep pace with advances in population health in other wealthy nations. Compared with other OECD nations, the US rank for various measures of mortality declined by between 5 and 9 ranks, depending on the metric. In contrast, the United States ranks high overall for age-standardized YLD rates compared with OECD countries, although agestandardized YLD rates are measured with wider uncertainty intervals than age-standardized YLL rates. Relative to other OECD nations, the United States has below-average agestandardized DALY rates for low back pain, stroke, falls, and colorectal cancer. It has higher than OECD mean rates for a number of leading diseases and injuries, such as COPD, road injury, diabetes, Alzheimer disease, and interpersonal violence.

In 2010, the United States had age-standardized rates above the mean for OECD countries for 16 of the top 30 diseases and injuries contributing to YLLs. At the same time, the US rates were below the mean in men for stroke, colorectal cancer, and falls

Table 4. Age-Standardized Life Expectancy and Healthy Life Expectancy (HALE) at Birth for Organisation for Economic Co-operation and Development Countries in 1990 and 2010, Both Sexes Combined, With 95\% Uncertainty Intervals

| Country | Life Expectancy at Birth, y |  |  |  | HALE at Birth, y |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1990 |  | 2010 |  | 1990 |  | 2010 |  |
|  | Estimate | Rank | Estimate | Rank | Estimate | Rank | Estimate | Rank |
| United States | 75.2 (75.2-75.2) | 20 (19-21) | 78.2 (78.2-78.3) | 27 (27-27) | 65.8 (64.0-67.4) | 14 (12-19) | 68.1 (66.3-69.8) | 26 (21-27) |
| Australia | 76.9 (76.8-76.9) | 11 (9-12) | 81.5 (81.4-81.6) | 4 (4-6) | 66.6 (64.7-68.4) | 9 (6-12) | 70.4 (68.2-72.3) | 5 (4-9) |
| Austria | 75.7 (75.6-75.8) | 15 (15-16) | 80.6 (80.5-80.7) | 13 (11-14) | 65.8 (63.6-67.6) | 15 (8-23) | 69.2 (66.8-71.3) | 15 (8-26) |
| Belgium | 75.9 (75.8-76.0) | 14 (14-14) | 79.5 (79.3-79.8) | 22 (20-24) | 65.8 (63.8-67.6) | 13 (12-20) | 68.7 (66.7-70.6) | 21 (15-25) |
| Canada | 77.2 (77.1-77.3) | 5 (5-5) | 80.6 (80.4-80.8) | 12 (10-14) | 67.1 (65.2-68.8) | 5 (2-9) | 69.7 (67.8-71.6) | 10 (7-16) |
| Chile | 72.9 (72.8-73.0) | 26 (25-26) | 78.5 (78.3-78.8) | 26 (26-26) | 63.4 (61.5-65.1) | 26 (24-28) | 68.6 (66.7-70.4) | 23 (14-27) |
| Czech Republic | 71.6 (71.5-71.7) | 28 (28-29) | 77.5 (77.4-77.6) | 28 (28-28) | 62.6 (60.8-64.3) | 29 (27-29) | 67.4 (65.5-69.3) | 28 (26-29) |
| Denmark | 75.2 (75.0-75.3) | 21 (19-22) | 78.9 (78.8-79.1) | 25 (25-25) | 65.2 (63.2-67.0) | 23 (15-24) | 67.9 (65.8-69.8) | 27 (23-28) |
| Estonia | 69.8 (69.5-70.1) | 32 (32-32) | 75.9 (75.6-76.2) | 30 (30-30) | 61.1 (59.3-62.6) | 32 (30-33) | 65.8 (64.0-67.5) | 31 (30-32) |
| Finland | 75.1 (75.0-75.2) | 22 (20-22) | 80.1 (79.9-80.2) | 17 (15-18) | 65.3 (63.4-67.0) | 20 (15-23) | 69.0 (67.0-70.9) | 16 (13-23) |
| France | 77.1 (77.0-77.1) | 6 (6-7) | 80.9 (80.7-81.1) | 9 (8-11) | 66.6 (64.6-68.4) | 11 (6-12) | 69.7 (67.6-71.6) | 11 (8-16) |
| Germany | 75.4 (75.3-75.4) | 17 (17-19) | 80.2 (80.1-80.4) | 15 (15-17) | 65.4 (63.5-67.1) | 18 (15-22) | 69.3 (67.3-71.1) | 13 (11-19) |
| Greece | 76.9 (76.8-77.0) | 9 (7-11) | 79.6 (79.4-79.8) | 21 (20-23) | 66.7 (64.7-68.7) | 8 (4-13) | 69.0 (66.9-70.8) | 17 (11-24) |
| Hungary | 69.4 (69.3-69.5) | 33 (33-33) | 74.5 (74.4-74.6) | 34 (33-34) | 60.3 (58.5-61.9) | 33 (32-33) | 64.3 (62.3-66.1) | 33 (33-34) |
| Iceland | 77.6 (77.3-78.0) | 3 (2-4) | 82.2 (81.7-82.6) | 2 (2-3) | 67.5 (65.6-69.4) | 2 (2-8) | 70.7 (68.5-72.7) | 4 (2-10) |
| Ireland | 74.8 (74.7-75.0) | 23 (23-23) | 79.9 (79.7-80.1) | 18 (16-20) | 65.2 (63.1-67.0) | 22 (13-24) | 69.0 (66.6-71.0) | 18 (9-27) |
| Israel | 76.4 (76.3-76.5) | 13 (13-13) | 81.1 (81.0-81.3) | 8 (8-9) | 66.3 (64.4-68.1) | 12 (8-14) | 69.9 (67.8-71.9) | 9 (6-14) |
| Italy | 77.0 (76.9-77.0) | 8 (7-10) | 81.5 (81.3-81.6) | 5 (4-7) | 66.8 (64.8-68.6) | 7 (5-12) | 70.3 (68.3-72.2) | 6 (4-9) |
| Japan | 79.1 (79.1-79.1) | 1 (1-1) | 82.6 (82.6-82.7) | 1 (1-1) | 69.9 (68.0-71.5) | 1 (1-1) | 73.0 (71.2-74.7) | 1 (1-1) |
| Luxembourg | 75.3 (75.0-75.6) | 18 (17-22) | 80.2 (79.8-80.5) | 16 (14-19) | 65.2 (63.0-67.2) | 19 (13-25) | 68.7 (66.2-70.8) | 19 (10-28) |
| Mexico | 71.5 (71.2-71.9) | 29 (28-29) | 75.5 (75.2-75.7) | 31 (31-33) | 62.9 (61.1-64.4) | 28 (26-29) | 66.9 (65.2-68.4) | 29 (28-30) |
| Netherlands | 77.0 (76.9-77.1) | 7 (6-8) | 80.6 (80.5-80.7) | 14 (11-14) | 66.6 (64.7-68.3) | 10 (6-12) | 69.3 (67.3-71.1) | 14 (11-21) |
| New Zealand | 75.3 (75.2-75.4) | 19 (17-21) | 80.7 (80.5-80.9) | 11 (10-14) | 65.3 (63.4-67.0) | 21 (15-23) | 69.6 (67.5-71.6) | 12 (8-16) |
| Norway | 76.8 (76.7-76.9) | 12 (11-12) | 80.8 (80.7-81.0) | 10 (9-12) | 65.5 (63.5-67.5) | 16 (13-23) | 68.6 (66.4-70.6) | 24 (16-26) |
| Poland | 70.9 (70.8-70.9) | $31(30-31)$ | 76.3 (76.3-76.4) | 29 (29-29) | 61.5 (59.3-63.3) | 30 (30-32) | 66.0 (63.6-67.9) | 30 (29-32) |
| Portugal | 74.3 (74.2-74.4) | 24 (24-24) | 79.4 (79.2-79.5) | 23 (22-24) | 64.3 (62.2-66.2) | 24 (20-27) | 68.6 (66.2-70.6) | 22 (12-28) |
| Slovakia | 71.0 (70.8-71.1) | 30 (30-31) | 75.4 (75.2-75.5) | 32 (31-33) | 61.4 (59.5-63.0) | 31 (30-32) | 65.5 (63.6-67.3) | 32 (30-32) |
| Slovenia | 73.1 (72.9-73.2) | 25 (25-26) | 79.3 (79.1-79.5) | 24 (22-24) | 63.4 (61.4-65.0) | 27 (24-29) | 68.4 (66.2-70.4) | 25 (16-27) |
| South Korea | 72.1 (71.6-72.6) | 27 (27-28) | 79.7 (79.6-79.8) | 20 (19-22) | 63.8 (62.1-65.4) | 25 (23-27) | 70.3 (68.4-72.0) | 7 (3-12) |
| Spain | 76.9 (76.9-77.0) | 10 (8-11) | 81.4 (81.2-81.5) | 7 (4-7) | 67.5 (65.7-69.1) | 3 (2-6) | 71.0 (69.1-72.7) | 2 (2-4) |
| Sweden | 77.6 (77.5-77.7) | 2 (2-4) | 81.4 (81.3-81.5) | 6 (4-7) | 67.1 (65.2-68.9) | 6 (3-11) | 70.1 (67.9-72.1) | 8 (4-13) |
| Switzerland | 77.5 (77.4-77.7) | 4 (2-4) | 82.2 (82.0-82.3) | 3 (2-3) | 67.5 (65.5-69.3) | 4 (2-7) | 70.9 (68.9-72.9) | 3 (2-7) |
| Turkey | 67.1 (66.1-68.1) | 34 (34-34) | 74.4 (72.8-75.7) | 33 (31-34) | 57.7 (55.8-59.4) | 34 (34-34) | 64.0 (61.7-66.2) | 34 (33-34) |
| United Kingdom | 75.7 (75.6-75.7) | 16 (15-16) | 79.9 (79.9-80.0) | 19 (17-19) | 65.5 (63.6-67.3) | 17 (14-22) | 68.8 (66.7-70.7) | 20 (16-24) |

and in women for stroke. The United States also had lower mean rates in 1990 for a longer list of diseases and injuries contributing to YLLs including stroke, self-harm, lower respiratory tract infections, colorectal cancer, congenital anomalies, cirrhosis, and stomach cancer. How much of the US advantage for these conditions is related to risk factors and how much is related to health care cannot be determined from the GBD data alone. Fiveyear survival for breast cancer and colorectal cancer are higher in the United States than in many OECD countries. ${ }^{75}$ Although the number of conditions for which the United States has belowaverage age-standardized rates is small, it does point out that poor health outcomes in the United States are not preordained. There are potential roles for public health programs, access to high-quality medical care, and policy and legislation in addressing both diseases and risk factors.

## Limitations

A study of this scope has many limitations, including most of those of the GBD 2010. ${ }^{3,19,25-27,29-31}$ First, there are inherent limitations of the data used to determine prevalence estimates and disability weights across countries. For some of the 1160 disabling sequelae, there are no data for some, or even many, countries. As detailed elsewhere, Bayesian statistical models have been used to estimate prevalence for these conditions in each country and by age, sex, and year. ${ }^{25}$ Comparisons of YLDs are influenced by the disability weights derived from the general population; to the extent that the general population did not understand the lay descriptions used to elicit judgments about levels of health, disability weights may be biased. Although Salomon et al ${ }^{26}$ found little evidence of variation in disability weights as a function of population or educational sta-

Figure 4. Rank of Age-Standardized YLL Rates Relative to the 34 OECD Countries in 2010


Numbers in cells indicate the ranks of each country for each cause, with 1 representing the best-performing country. Countries are sorted on the basis of age-standardized all-cause years of life lost (YLLs) for 2010. Diseases and injuries contributing to YLLs are ordered by the difference between the US rate and the lowest rate in the Organisation for Economic Co-operation and

Development (OECD) countries for each cause. Colors indicate whether the age-standardized YLL rate for the country is significantly lower (green), indistinguishable (yellow), or higher (red) from the mean age-standardized YLL rate across the OECD countries. HIV indicates human immunodeficiency virus.
tus, it is possible that disability weights may vary across different populations or across socioeconomic or race and ethnicity groups within populations. To highlight differences in epidemiology, cross-country comparisons should use a common set of weights. However, if disability weights are found to vary, local weights could be used for within-country studies. The ongoing assessment of the burden of disease for the United States would benefit from a systematic evaluation of where the data are most limited. Important sources of data may not have been identified or been available or these data may not have been collected.

Second, there are limitations related to the extent, quality, and consistency of some information used in the analyses and estimates in this study. The reporting of $95 \%$ uncertainty intervals that incorporate both sampling error and error from
model estimation provides some information on the extent and quality of the information available for the United States. Uncertainty could be underestimated for a range of reasons, such as unrecognized bias in published studies. However, the nature of the estimation process both for causes of death and the prevalence of sequelae more generally exaggerate uncertainty intervals in a high-income country such as the United States. These wide uncertainty intervals limit the ability to determine whether a country is above or below the OECD mean for YLDs. Country ranks across age-standardized YLL rates could still be affected by differences in national death certification practice, although after careful and detailed examination of the cause-of-death data, we have not identified any reason to suspect that this is a major problem in the United States. ${ }^{30}$ However, some of the increase in Alzheimer disease
from 1990 to 2010 may be related to changes in certification and coding. ${ }^{72}$ Concerns have been raised that in some countries, variable implementation of the World Health Organization's definition of a live birth may affect comparisons of early neonatal death rates ${ }^{76}$ across countries; because early neonatal deaths account for only $0.5 \%$ of deaths and $2.6 \%$ of YLLs, these considerations are unlikely to affect the comparisons shown here. However, the same problems related to how countries define and count diseases, injuries, and risk factors could affect estimates of other diseases included in these analysis.

Third, the analysis of risk factors in this study focused on behavioral, environmental, and metabolic risks and did not evaluate the social determinants of health. The important role of social determinants of health ${ }^{5,6}$ was not quantified in the GBD 2010, largely because of the study requirement that evidence meet the World Cancer Research Fund criteria of convincing or probable evidence and that epidemiological data be available to estimate effect sizes for a risk factor on specific causes of death or disability. Much of the substantial body of evidence on the important influence of socioeconomic factors relates determinants such as income, education, and inequality to all-cause outcomes. The World Cancer Research Fund criteria emphasize consistency of evidence whether across trials or cohort studies. However, given the complex pathways through which socioeconomic factors influence health in different communities, effect sizes often vary. ${ }^{5,77-79}$ In some cases, intervention studies for income and education have yielded results that are not entirely consistent with those of observational studies. ${ }^{80,81}$ Authoritative reviews ${ }^{18,44,78,82}$ nevertheless support the critical importance of these factors in determining population health. The
absence of these in this current assessment should not be taken as implying that they are less important than the more proximal factors studied here. Despite their omission, the evidence suggests that interventions to reduce behavioral, environmental, and metabolic risks can have substantial benefits across diverse socioeconomic groups. ${ }^{70,83,84}$

## Conclusion

Overall, population health in the United States has improved from 1990 to 2010. Life expectancy at birth and HALE have increased and all-cause death rates at all ages have decreased. Although life span has increased, rates of age-specific YLDs have remained stable, and morbidity and chronic disability now account for nearly half of the health burden in the United States. However, improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations. Regular assessments of the local burden of disease and matching information on health expenditures for the same disease and injury categories could allow for a more direct assessment of how changes in health spending have affected or, indeed, not affected changes in the burden of disease and may provide insights into where the US health care system could most effectively invest its resources to obtain maximum benefits for the nation's population health. In many cases, the best investments for improving population health would likely be public health programs and multisectoral action to address risks such as physical inactivity, diet, ambient particulate pollution, and alcohol and tobacco consumption.

## ARTICLE INFORMATION

Published Online: July 10, 2013.
doi:10.1001/jama.2013.13805.
US Burden of Disease Collaborators: Christopher J. L. Murray, MD, DPhil; Jerry Abraham, MPH; Mohammed K. Ali, MBChB, MSc; Miriam Alvarado, BA; Charles Atkinson, BS; Larry M. Baddour, MD; David H. Bartels, BA; Emelia J. Benjamin, MD, ScM; Kavi Bhalla, PhD; Gretchen Birbeck, MD; Ian Bolliger, AB; Roy Burstein, BA; Emily Carnahan, BA; Honglei Chen, PhD; David Chou, BA; Sumeet S. Chugh, MD; Aaron Cohen, MPH, DSc; K. Ellicott Colson, BA; Leslie T. Cooper, MD; William Couser, MD; Michael H. Criqui, MD, MPH; Kaustubh C. Dabhadkar, MBBS, MPH; Nabila Dahodwala, MD, MS; Goodarz Danaei, DrSc, MS; Robert P. Dellavalle, MD, PhD, MSPH; Don C. Des Jarlais, PhD; Daniel Dicker, BS; Eric L. Ding, ScD; E. Ray Dorsey, MD, MBA; Herbert Duber, MD, MPH; Beth E. Ebel, MD, MSc, MPH; Rebecca E. Engell, BA; Majid Ezzati, PhD; David T. Felson, MD; Mariel M. Finucane, PhD; Seth Flaxman, BA; Abraham D. Flaxman, PhD; Thomas Fleming, BA; Mohammad H. Forouzanfar, MD, PhD; Greg Freedman, BA; Michael K. Freeman, BA; Sherine E. Gabriel, MD; Emmanuela Gakidou, PhD; Richard F. Gillum, MD; Diego Gonzalez-Medina, BA; Richard Gosselin, MD; Bridget Grant, PhD; Hialy R. Gutierrez, BS; Holly Hagan, PhD; Rasmus Havmoeller, MD, PhD; Howard Hoffman, MA; Kathryn H. Jacobsen, PhD; Spencer L. James, MPHc; Rashmi Jasrasaria, BA; Sudha

Jayaraman, MD, MSc; Nicole Johns, MPH; Nicholas Kassebaum, MD; Shahab Khatibzadeh, MD, MPH; Lisa Marie Knowlton, MD, MPH; Qing Lan, PhD; Janet L. Leasher, OD, MPH; Stephen Lim, PhD; John Kent Lin, AB; Steven E. Lipshultz, MD; Stephanie London, MD, DrPH; Rafael Lozano, MD, PhD; Yuan Lu, MSc; Michael F. MacIntyre, EdM; Leslie Mallinger, MPH; Mary M. McDermott, MD; Michele Meltzer, MD, MBE; George A. Mensah, MD; Catherine Michaud, MD, PhD; Ted R. Miller, PhD; Charles Mock, MD, PhD; Terrie E. Moffitt, PhD; Ali A. Mokdad, MD, MS; Ali H. Mokdad, PhD; Andrew E. Moran, MD, MPH; Dariush Mozaffarian, MD, DrPH; Tasha Murphy, PhD; Mohsen Naghavi, PhD; K. M. Venkat Narayan, MD; Robert G. Nelson, MD, PhD; Casey Olives, PhD; Saad B. Omer, MBBS, MPH, PhD; Katrina Ortblad, BA; Bart Ostro, PhD; Pamela M. Pelizzari, MPH; David Phillips, BS; C. Arden Pope III, PhD; Murugesan Raju, PhD; Dharani Ranganathan, BS; Homie Razavi, PhD; Beate Ritz, MD, PhD; Frederick P. Rivara, MD, MPH; Thomas Roberts, BA; Ralph L. Sacco, MD, MS; Joshua A. Salomon, PhD; Uchechukwu Sampson, MD, MPH, MBA, MSc(Oxon); Ella Sanman, BS; Amir Sapkota, PhD; David C. Schwebel, PhD; Saeid Shahraz, MD; Kenji Shibuya, MD, DrPH; Rupak Shivakoti, BA; Donald Silberberg, MD; Gitanjali M. Singh, PhD; David Singh, MD; Jasvinder A. Singh, MBBS, MPH; David A. Sleet, PhD; Kyle Steenland, PhD; Mohammad Tavakkoli, MD, MPH, MSc; Jennifer A. Taylor, PhD, MPH; George D. Thurston, ScD; Jeffrey A. Towbin, MD; Monica S. Vavilala, MD; Theo Vos, PhD;

Gregory R. Wagner, MD; Martin A. Weinstock, MD PhD; Marc G. Weisskopf, PhD; James D. Wilkinson, MD, MPH; Sarah Wulf, MPH; Azadeh Zabetian, MD; Alan D. Lopez, PhD.
US Burden of Disease Collaborators Affiliations: Institute for Health Metrics and Evaluation, Seattle, Washington (Murray, Alvarado, Atkinson, Bolliger, Burstein, Carnahan, Chou, Colson, Dicker, Duber, Engell, A. D. Flaxman, Fleming, Forouzanfar, Freedman, Freeman, Gakidou, Gonzalez-Medina, James, Jasrasaria, Johns, Lim, MacIntyre, Mallinger, A. A. Mokdad, A. H. Mokdad, Murphy, Naghavi, Ortblad, Phillips, Ranganathan, Roberts, Sanman, Vos, Wulf); University of Washington, Seattle (Couser, Ebel, Kassebaum, Mock, Olives, Rivara, Vavilala); University of Texas School of Medicine, San Antonio (Abraham); Rollins School of Public Health, Emory University, Atlanta, Georgia (Omer, Steenland); Emory University, Atlanta, Georgia (Ali, Dabhadkar, Narayan, Zabetian); Mayo Clinic, Rochester, Minnesota (Baddour, Gabriel); Harvard School of Public Health, Boston, Massachusetts (Danaei, Ding, Finucane, Khatibzadeh, Knowlton, Lin, Lu, Salomon, G. M. Singh, Tavakkoli, Weisskopf); Harvard Medical School, Boston, Massachusetts (Bartels, Jayaraman, Mozaffarian); Harvard University, Boston, Massachusetts (Bhalla); Boston University School of Medicine, Boston, Massachusetts (Benjamin); Boston University, Boston, Massachusetts (Felson); Michigan State University, East Lansing (Birbeck); National Institute of Environmental Health Sciences, Research

Triangle Park, North Carolina (Chen, London); Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland (Lan); National Institutes of Health, Bethesda, Maryland (Grant, Hoffman, Mensah); National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (Nelson); National Institute for Occupational Safety and Health, Baltimore, Maryland (Wagner); Cedars-Sinai Medical Center, Los Angeles, California (Chugh, Havmoeller); Karolinska Institute, Stockholm, Sweden (Havmoeller); Health Effects Institute, Boston, Massachusetts (Cohen); Loyola University Medical School, Chicago, Illinois (Cooper); University of California, San Diego, La Jolla (Criqui); University of Pennsylvania, Philadelphia (Dahodwala, Silberberg); Denver VA Medical Center, Denver, Colorado (Dellavalle); Beth Israel Medical Center, New York, New York (Des Jarlais); Johns Hopkins University, Baltimore, Maryland (Dorsey, Shivakoti); MRC-HPA Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, England (Ezzati); Carnegie Mellon University, Pittsburgh, Pennsylvania (S. Flaxman); Howard University College of Medicine, Washington, DC (Gillum); University of California, San Francisco (Gosselin); Mailman School of Public Health, New York, New York (Gutierrez); Columbia University, New York, New York (Moran); New York University, New York, New York (Hagan, Thurston); George Mason University, Fairfax, Virginia (Jacobsen); Nova Southeastern University, Fort Lauderdale, Florida (Leasher); Miller School of Medicine, University of Miami, Miami, Florida (Lipshultz, Sacco, Wilkinson); School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia (Lopez); Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico (Lozano); Northwestern University Feinberg School of Medicine, Evanston, Illinois (McDermott); Thomas Jefferson University, Philadelphia, Pennsylvania (Meltzer); China Medical Board, Boston, Massachusetts (Michaud); Pacific Institute for Research and Evaluation, Calverton, Maryland (Miller); Duke University, Durham, North Carolina (Moffitt); Brigham and Women's Hospital, Boston, Massachusetts (Mozaffarian); California Environmental Protection Agency, Sacramento (Ostro); Centers for Medicare \& Medicaid Services, Baltimore, Maryland (Pelizzari); Brigham Young University, Provo, Utah (Pope); Mason Eye Institute, University of Missouri, Columbia (Raju); Center for Disease Analysis, Louisville, Colorado (Razavi); University of California, Los Angeles (Ritz); Vanderbilt University, Nashville, Tennessee (Sampson); University of Maryland School of Public Health, College Park (Sapkota); University of Alabama at Birmingham (Schwebel, J. A. Singh); Brandeis University, Waltham, Massachusetts (Shahraz); Department of Global Health Policy, University of Tokyo, Tokyo, Japan (Shibuya); Queens Medical Center, Honolulu, Hawaii (D. Singh); National Center for Injury Prevention and Control, Atlanta, Georgia (Sleet); Drexel University School of Public Health, Philadelphia, Pennsylvania (Taylor); Cincinnati Children's Hospital, Cincinnati, Ohio (Towbin); Brown University, Providence, Rhode Island (Weinstock). Dr Rivara is also Editor, JAMA Pediatrics.

Author Contributions: Dr Murray had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Atkinson, Bhalla, Birbeck, Burstein, Chou, Dellavalle, Danaei, Ezzati, Fahimi, A. D. Flaxman, Foreman, Gabriel, Gakidou, Kassebaum, Khatibzadeh, Lim, Lipshultz, London, Lopez, MacIntyre, A.H. Mokdad, A. Moran, Mozaffarian, Murphy, Naghavi, Pope, Roberts, Salomon, Schwebel, Shahraz, Sleet, Murray. Acquisition of data: Abraham, Ali, Atkinson, Bartels, Bhalla, Birbeck, Burstein, Chen, Criqui, Dahodwala, Jarlais, Ding, Dorsey, Ebel, Ezzati, Fahimi, S. Flaxman, A. D. Flaxman, Gonzalez-Medina, Grant, Hagan, Hoffman, Kassebaum, Khatibzadeh, Leasher, Lin, Lipshultz, Lozano, Lu, Mallinger, McDermott, Micha, Miller, A. A. Mokdad, A. H. Mokdad, Mozaffarian, Naghavi, Narayan, Omer, Pelizzari, Phillips, Ranganathan, Rivara, Roberts, Sampson, Sanman, Sapkota, Schwebel, Shahraz, Shivakoti, G. Singh, D. Singh, Tavakkoli, Towbin, Wilkinson, Zabetian, Murray.
Analysis and interpretation of data: Abraham, Ali, Alvarado, Atkinson, Baddour, Benjamin, Bhalla, Birbeck, Bolliger, Burstein, Carnahan, Chou, Chugh, Cohen, Colson, Cooper, Couser, Criqui, Dabhadkar, Dellavalle, Jarlais, Dicker, Dorsey, Duber, Ebel, Engell, Ezzati, Felson, Finucane, S. Flaxman, A. D. Flaxman, Fleming, Foreman, Forouzanfar, Freedman, Freeman, Gakidou, Gillum, Gonzalez-Medina, Gosselin, Gutierrez, Hagan, Havmoeller, Hoffman, Jacobsen, James, Jasrasaria, Jayaraman, Johns, Kassebaum, Khatibzadeh, Lan, Leasher, Lim, Lipshultz, London, Lopez, Lozano, Lu, Mallinger, Meltzer, Mensah, Michaud, Miller, Mock, Moffitt, A. A. Mokdad, A. H. Mokdad, A. Moran, Naghavi, Narayan, Nelson, Olives, Omer, Ortblad, Ostro, Pelizzari, Phillips, Raju, Razavi, Ritz, Roberts, Sacco, Salomon, Sampson, Schwebel, Shahraz, Shibuya, Silberberg, J. Singh, Steenland, Taylor, Thurston, Vavilala, Vos, Wagner, Weinstock, Weisskopf, Wulf, Murray.
Drafting of the manuscript: Birbeck, Fleming, Gakidou, Havmoeller, James, Jayaraman, Lozano, MacIntyre, Meltzer, Naghavi, Roberts, Vavilala, Vos, Murray.
Critical revision of the manuscript for important intellectual content: Ali, Alvarado, Atkinson, Baddour, Bartels, Benjamin, Bhalla, Birbeck, Bolliger, Burstein, Carnahan, Chen, Chou, Chugh, Cohen, Colson, Cooper, Couser, Criqui, Dabhadkar, Dahodwala, Dellavalle, Jarlais, Danaei, Dicker, Ding, Dorsey, Duber, Ebel, Engell, Ezzati, Fahimi, Felson, Finucane, S. Flaxman, A. D. Flaxman, Foreman, Forouzanfar, Freedman, Freeman, Gabriel, Gillum, Gonzalez-Medina, Gosselin, Grant, Gutierrez, Hagan, Havmoeller, Hoffman, Jacobsen, Jasrasaria, Jayaraman, Johns, Kassebaum, Khatibzadeh, Lan, Leasher, Lim, Lin, Lipshultz, London, Lopez, Lu, Mallinger, McDermott, Meltzer, Mensah, Micha, Michaud, Miller, Mock, Moffitt, A. A. Mokdad, A. H. Mokdad, A. Moran, Mozaffarian, Murphy, Narayan, Nelson, Olives, Omer, Ortblad, Ostro, Pelizzari, Phillips, Pope, Raju, Ranganathan, Razavi, Ritz, Rivara, Roberts, Sacco, Salomon, Sampson, Sanman, Sapkota, Schwebel, Shahraz, Shibuya, Shivakoti, Silberberg, G. Singh, D. Singh, J. Singh, Sleet, Steenland, Tavakkoli, Taylor, Thurston, Towbin, Vavilala, Vos, Wagner, Weinstock, Weisskopf, Wilkinson, Wulf, Zabetian, Murray. Statistical analysis: Abraham, Alvarado, Atkinson, Bhalla, Bolliger, Burstein, Carnahan, Chou, Colson,

Dabhadkar, Danaei, Dicker, Engell, Finucane, S. Flaxman, A. D. Flaxman, Foreman, Forouzanfar, Freedman, Freeman, Gillum, Gonzalez-Medina, Grant, Havmoeller, Hoffman, Jacobsen, James, Jasrasaria, Johns, Kassebaum, Khatibzadeh, Lim, Lin, MacIntyre, Mallinger, A. A. Mokdad, A. Moran, Naghavi, Olives, Omer, Ortblad, Pelizzari, Phillips, Ranganathan, Razavi, Roberts, Salomon, Sanman, Shahraz, Shibuya, G. Singh, Steenland, Tavakkoli, Vos, Wulf, Murray.
Obtained funding: A. H. Mokdad, Murray. Administrative, technical, or material support: Ali, Atkinson, Birbeck, Ebel, Hoffman, Lipshultz, Mensah, Micha, Michaud, A. H. Mokdad, A. Moran, Mozaffarian, Murphy, Narayan, Pelizzari, Phillips, Pope, Shivakoti, J. Singh, Taylor, Thurston, Towbin, Vavilala, Weinstock, Weisskopf.
Study supervision: Baddour, Birbeck, Criqui, Ezzati, A. D. Flaxman, Gakidou, Hoffman, Kassebaum, Lim, Lipshultz, Lopez, MacIntyre, A. H. Mokdad, Murphy, Salomon, Silberberg, Thurston, Wilkinson, Murray.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Benjamin reports consulting fee/honoraria from Circulation as associate editor. Dr Couser reports fees for data safety monitoring board participation from Lilly and travel/meeting expenses from the International Society of Nephrology. Dr Dellavalle reports royalties from UpToDate and the Journal of the American Academy of Dermatology. Dr Gillum reports consultancy as an associate editor for Elsevier. Dr Lopez reports consultancy for IHME. Dr McDermott reports consulting fee from Ironwood Pharmaceuticals. Dr Mensah reports stock/stock options in PepsiCo, travel/meeting expenses from Chevron, and an honorarium from Elsevier. Dr Moffitt reports board membership with Nuffield Foundation. Dr Ostro reports consultancy for the World Bank and grants/grants pending from the US EPA. Dr Schwebel reports consultancy for ORCAS Inc, IRIS, and Marshfield Clinics, expert testimony for Carr and Carr, and grants/grants pending from Carr and Carr, Morris Animal Foundation, and Blue Dog Foundation, payment for lectures/speakers bureau from various university and government entities, and royalties from Erlbaum. Dr D. Singh reports payment for lectures/speakers bureau from Bristol Myers. Dr Moran reports travel/meeting expenses from the Institute for Health Metrics and Evaluation. Dr J. Singh reports consultancy for Savient, Takeda, URL, Novartis, Ardea, Allergan, and Regeneron and grants/grants pending from Takeda and Savient. He is on the steering committee of OMERACT. No other disclosures were reported.
Funding/Support: This study is supported in part by the Intramural Program of the National Institutes of Health, the National Institute of Environmental Health Sciences, and in part by the Bill and Melinda Gates Foundation.
Role of the Sponsors: The sponsors of the study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; or decision to submit the manuscript for publication.
Disclaimer: Dr McDermott (senior editor of JAMA) and Dr Rivara (editor in chief of JAMA Pediatrics) were not involved in the editorial review of or decision to publish this article.

Additional Contributions: We acknowledge all additional collaborators who were part of the Global Burden of Disease 2010 Study.

## REFERENCES

1. OECD health data 2012-frequently requested data. http://www.oecd.org/health/health-systems /oecdhealthdata2012-frequentlyrequested -data.htm. Accessed April 29, 2013.
2. World Health Organization. Global health expenditure database. http://www.who.int/nha /expenditure_database/en/. Accessed April 29, 2013.
3. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2071-2094. doi:10.1016/S0140 -6736(12)61719-X.
4. Woolf SH, Aron L, eds. US Health in International Perspective: Shorter Lives, Poorer Health. Washington, DC: National Academies Press; 2013. http://www.nap.edu/openbook.php?record_id $=13497$.
5. Williams DR, Collins C. US socioeconomic and racial differences in health: patterns and explanations. Annu Rev Sociol. 1995;21:349.
6. Lantz PMHJ, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA. 1998;279(21):1703-1708. doi:10.1001 /jama.279.21.1703.
7. Kindig DA, Cheng ER. Even as mortality fell in most US counties, female mortality nonetheless rose in $42.8 \%$ of counties from 1992 to 2006. Health Aff (Millwood). 2013;32(3):451-458. doi:10.1377/hlthaff.2011.0892.
8. Ezzati M, Friedman AB, Kulkarni SC, Murray CJL. The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States. PLoS Med. 2008;5(4):e66.
doi:10.1371/journal.pmed.0050066.
9. Patient Protection and Affordable Care Act (2010 HR 3590). http://www.govtrack.us/congress /bills/111/hr3590. Accessed April 29, 2013.
10. Amos A, Greaves L, Nichter M, Bloch M Women and tobacco: a call for including gender in tobacco control research, policy and practice. Tob Control. 2012;21(2):236-243. doi:10.1136 /tobaccocontrol-2011-050280.
11. Crawford D, Jeffery RW, Ball K. Obesity Epidemiology: From Aetiology to Public Health. Oxford, England: Oxford University Press; 2010.
12. Tobacco Use Screening and Counseling During Physician Office Visits Among Adults-National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009. http://www.cdc.gov/mmwR/preview/mmwrhtml /su6102a7.htm. Accessed June 11, 2013.
13. Sharma LL, Teret SP, Brownell KD. The food industry and self-regulation: standards to promote success and to avoid public health failures. Am J Public Health. 2010;100(2):240-246.
doi:10.2105/AJPH.2009.160960.
14. Wallinga D. Agricultural policy and childhood obesity: a food systems and public health commentary. Health Aff(Millwood). 2010;29(3):405-410. doi:10.1377/hlthaff.2010.0102.
15. Brownell KD, Farley T, Willett WC, et al. The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med. 2009;361(16):1599-1605. doi:10.1056 /NEJMhpr0905723.
16. Gordon-Larsen P, Nelson MC, Page P, Popkin $B M$. Inequality in the built environment underlies key health disparities in physical activity and obesity. Pediatrics. 2006;117(2):417-424. doi:10.1542/peds.2005-0058.
17. Jackson RJ. The impact of the built environment on health: an emerging field. Am J Public Health. 2003;93(9):1382-1384.
18. Adler NEBW, Boyce WT, Chesney MA, Folkman S, Syme SL. Socioeconomic inequalities in health: no easy solution. JAMA. 1993;269(24):3140-3145. doi:10.1001/jama.1993.03500240084031.
19. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet. 2012;380(9859):2063-2066.
20. Michaud CM, McKenna MT, Begg S, et al. The burden of disease and injury in the United States 1996. Popul Health Metr. 2006;4:11.
doi:10.1186/1478-7954-4-11.
21. Michaud CMMC, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA. 2001;285(5):535-539. doi:10.1001/jama.285.5.535
22. McKenna MT, Michaud CM, Murray CJL, Marks JS. Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med. 2005;28(5):415-423. doi:10.1016
/j.amepre.2005.02.009.
23. Kominski GF, Simon PA, Ho A, Luck J, Lim Y-W, Fielding JE. Assessing the burden of disease and injury in Los Angeles County using disability-adjusted life years. 2002;117(2):185-191.
24. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6(4):e1000058. doi:10.1371/ journal.pmed. 1000058.
25. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. doi:10.1016/S0140-6736(12)61729-2.
26. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 Lancet. 2012;380(9859):2129-2143. doi:10.1016/S0140-6736(12)61680-8
27. Salomon JA, Wang H, Freeman MK, et al Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012;380(9859):2144-2162. doi:10.1016/S0140 -6736(12)61690-0.
28. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet. 2012;380(9859):2055-2058. doi:10.1016/S0140 6736(12)62134-5.
29. Murray CJL, Vos T, Lozano R, et al Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease

Study 2010. Lancet. 2012;380(9859):2197-2223. doi:10.1016/S0140-6736(12)61689-4.
30. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128. doi:10.1016/S0140-6736(12)61728-0.
31. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-2260. doi:10.1016/S0140-6736(12)61766-8.
32. Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet. 2013;381(9871): 997-1020. doi:10.1016/S0140-6736(13)60355-4.
33. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14(1):1. doi:10.1186/1129-2377-14-1.
34. Olives C, Myerson R, Mokdad AH, Murray CJL, Lim SS. Prevalence, awareness, treatment, and control of hypertension in United States counties, 2001-2009. PLoS One. 2013;8(4):e60308. doi:10.1371/journal.pone.0060308.
35. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987-2015.
36. National Center for Health Statistics. National Health and Nutrition Examination Survey Questionnaire. Hyattsville, MD: National Center for Health Statistics. http://www.cdc.gov/nchs/nhanes /nhanes_questionnaires.htm. Accessed March 28, 2013.
37. Healthcare Cost and Utilization Project. SID related reports. http://www.hcup-us.ahrq.gov/db /state/sidrelatedreports.jsp. April 5, 2013.
38. Canadian Institute for Health Information. National Ambulatory Care Reporting System 2002-2009 [data set]. Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2011.
39. National Center for Health Statistics. National Ambulatory Medical Care Survey. Hyattsville, MD: National Center for Health Statistics; 1993.
40. National Center for Health Statistics. National Hospital Ambulatory Medical Care Survey. Hyattsville, MD: National Center for Health Statistics; 1992.
41. Agency for Healthcare Research and Quality. US Medical Expenditure Panel Survey 2000-2009. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
42. National Comorbidity Survey. NCS and NCRS Data. http://www.hcp.med.harvard.edu/ncs/ncs _data.php. Accessed April 5, 2013.
43. Tomz M, Wittenberg J, King G. Clarify: Software for Interpreting and Presenting Statistical Results. http://econpapers.repec.org/article/jssjstsof/08 _3AiO1.htm. Accessed June 11, 2013.
44. Murray CJL, Lopez AD. On the comparable quantification of health risks: lessons from the Global Burden of Disease study. http://journals.Iww .com/epidem/Fulltext/1999/09000/On_the _Comparable_Quantification_of_Health_Risks_ 29 .aspx. Accessed June 11, 2013.
45. World Cancer Research Fund, American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
46. Mathers CD, Salomon JA, Ezzati M, Begg S, Hoorn SV, Lopez AD. Sensitivity and uncertainty analyses for burden of disease and risk factor estimates. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, eds. Global Burden of Disease and Risk Factors. Washington, DC: World Bank; 2006.
47. Salomon JA, Murray CJL. The epidemiologic transition revisited: compositional models for causes of death by age and sex. Popul Dev Rev. 2002;28(2):205-228. doi:10.1111/j. 1728 -4457.2002.00205.x.
48. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age Standardization of Rates: A New WHO Standard. Geneva, Switzerland: World Health Organization; 2001. http://www.who.int/healthinfo/paper31.pdf. Accessed April 4, 2013.
49. Anderson GF, Petrosyan V, Hussey PS, Fund C. Multinational Comparisons of Health Systems Data 2002. New York, NY: Commonwealth Fund; 2002. http://www.commonwealthfund.org///media/Files /Publications/Chartbook/1999/Oct/Health\%2Oand \%20Population\%20Aging\%20\%20A \%20Multinational\%20Comparison/Anderson _healthpop_multi99_354\%20pdf.pdf. Accessed April 29, 2013.
50. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-3230.
51. Collins F. FY 2012 Budget Submission. Bethesda, MD: National Institutes of Health; 2011.
52. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. Circulation. 2011;123(24):2870-2891. doi:10.1161/CIRCULATIONAHA.110.968735.
53. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4): 586-613. doi:10.1161
/CIRCULATIONAHA.109.192703.
54. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-1290. doi:10.1056/NEJMoa1200303.
55. Appel LJ, Moore TJ, Obarzanek E, et al; DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure.
N Engl J Med. 1997;336(16):1117-1124.

## doi:10.1056/NEJM199704173361601.

56. Appel LJSF, Sacks FM, Carey VJ, et al; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294(19):2455-2464. doi:10.1001 /jama.294.19.2455.
57. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term
weight gain in women and men. $N$ Engl J Med. 2011;364(25):2392-2404. doi:10.1056 /NEJMoa1014296.
58. Dwyer-Lindgren L, Freedman GD, Engell RE, et al. Prevalence of physical activity and obesity in US counties, 2001-2011: a road map for action. Popul Health Metr. 2013;11:7.
59. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71-82. doi:10.1001 /jama.2012.113905.
60. Whitlock G, Lewington S, Sherliker P, et al; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096. doi:10.1016/S0140-6736(09)60318-4.
61. Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M; Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia-Pacific region: an overview of 33 cohorts involving 310000 participants. Int J Epidemiol. 2004;33(4):751-758. doi:10.1093/ije /dyh163.
62. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-1095. doi:10.1016/S0140-6736(11)60105-0.
63. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of US adults. $N$ Engl $J$ Med. 1999;341(15):1097-1105. doi:10.1056 /NEJM199910073411501.
64. Peto R, Whitlock G, Jha P. Effects of obesity and smoking on US life expectancy. $N$ Engl $J$ Med. 2010;362(9):855-856. doi:10.1056 /NEJMc1000079.
65. Willett WCHF, Hu FB, Thun M. Overweight, obesity, and all-cause mortality. JAMA. 2013;309(16):1681-1682. doi:10.1001 /jama.2013.3075.
66. Cullen KW, Thompson D, Boushey C, Konzelmann K, Chen T-A. Evaluation of a web-based program promoting healthy eating and physical activity for adolescents: Teen Choice: Food and Fitness [published online June 6, 2013]. Health Educ Res. doi:10.1093/her/cyt059.
67. Butson AR. Utilization of high-fat diet at low temperatures. Lancet. 1950;1(6613):993-994.
68. Association AD; American Diabetes

Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033-1046. doi:10.2337/dc12-2625.
69. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624. doi:10.1056 /NEJMsa1213829.
70. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoaO12512.
71. Whitelegg J, Haq G. Vision zero: adopting a target of zero for road traffic fatalities and serious injuries. 2006. http://www.sei-international.org /mediamanager/documents/Publications/Future /vision_zero_FinalReportMarch06.pdf. Accessed April 30, 2013.
72. Izquierdo FA, Ramírez BA, McWilliams JMM, Ayuso JP. The endurance of the effects of the penalty point system in Spain 3 years after: main influencing factors. Accid Anal Prev.
2011;43(3):911-922. doi:10.1016/j.aap.2010.11.014.
73. Redelmeier DA, McLellan BA. Modern medicine is neglecting road traffic crashes. PLoS Med. 2013;10(6):e1001463. doi:10.1371 /journal.pmed. 1001463.
74. National Center for Injury Prevention and Control. Injury prevention and control: motor vehicle safety. http://www.cdc.gov /MotorVehicleSafety/costs/policy.html. Accessed April 3, 2013.
75. Coleman MP, Quaresma M, Berrino F, et al; CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730-756. doi:10.1016/S1470-2045(08)70179-7.
76. Kramer MS, Platt RW, Yang H, Haglund B, Cnattingius S, Bergsjo P. Registration artifacts in international comparisons of infant mortality. Paediatr Perinat Epidemiol. 2002;16(1):16-22.
77. Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health. 2010;100(suppl 1):S186-S196. doi:10.2105/AJPH.2009.166082.
78. Braveman P, Egerter S, Williams DR. The social determinants of health: coming of age. Annu Rev Public Health. 2011;32(1):381-398. doi:10.1146/annurev-publhealth-031210-101218.
79. Williams DR, Mohammed SA, Leavell J, Collins C. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. Ann N Y Acad Sci. 2010;1186(1): 69-101. doi:10.1111/j.1749-6632.2009.05339.x.
80. Connor J, Rodgers A, Priest P. Randomised studies of income supplementation: a lost opportunity to assess health outcomes. J Epidemiol Community Health. 1999;53(11):725-730. doi:10.1136/jech.53.11.725.
81. Chen JT, Beckfield J, Waterman PD, Krieger N. Can changes in the distributions of and associations between education and income bias temporal comparisons of health disparities? an exploration with causal graphs and simulations. Am J Epidemiol. 2013;177(9):870-881. doi:10.1093/aje/kwt041.
82. Dowd JB, Albright J, Raghunathan TE, Schoeni RF, Leclere F, Kaplan GA. Deeper and wider: income and mortality in the USA over 3 decades. Int J Epidemiol. 2011;40(1):183-188. doi:10.1093/ije /dyq189.
83. Fisher ES. Paying for performance-risks and recommendations. N Engl J Med. 2006;355(18): 1845-1847. doi:10.1056/NEJMp068221.
84. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. $N$ Engl $J$ Med. 2009;360(7):699-709. doi:10.1056/ NEJMsa0806819.

